

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

**BMJ** Open

# **BMJ Open**

## A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children

| Journal:                         | BMJ Open   |
|----------------------------------|--|
| Manuscript ID                    | bmjopen-2021-057892  |
| Article Type:                    | Protocol   |
| Date Submitted by the<br>Author: | 01-Oct-2021  |
| Complete List of Authors:        | Ali, Samina; University of Alberta, Pediatrics<br>Rajagopal, Manasi; University of Alberta, Pediatrics<br>Stinson, Jennifer; Toronto SickKids<br>Ma, Keon; University of Calgary Cumming School of Medicine, Pediatrics<br>Vandermeer, Ben; University of Alberta, Pediatrics<br>Felkar, Bailey; London Health Sciences Centre, Pediatrics<br>Schreiner, Kurt; University of Alberta, Pediatric Parents' Advisory Group<br>Proctor, Amanda; Alberta Health Services<br>Plume, Jennifer; Alberta Health Services<br>Hartling, Lisa; University of Alberta, Pediatrics |
| Keywords:                        | ACCIDENT & EMERGENCY MEDICINE, Pain management <<br>ANAESTHETICS, Paediatric A&E and ambulatory care < PAEDIATRICS,<br>PAIN MANAGEMENT   |
|                                  | ·  |



<u>Title:</u> A randomized controlled trial of virtual reality-based distraction for venipuncturerelated distress in children Lay Title: Virtual Reality Based Distraction for Painful Procedures in Children

<u>Authorship:</u> Samina Ali MDCM<sup>1,2,\*</sup>, Manasi Rajagopal MBT<sup>1</sup>, Jennifer Stinson<sup>3</sup>, Keon Ma MD<sup>4</sup>, Ben Vandermeer MSc<sup>5</sup>, Bailey Felkar MS CCLS<sup>6</sup>, Kurt Schreiner MPM<sup>7</sup>, Amanda Proctor<sup>8</sup>, Jennifer Plume BM, MA MTA<sup>9</sup>, Lisa Hartling PhD<sup>1,5</sup>

1 Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada

2 Women & Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada

3 Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children and the Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada

4 Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

5 Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada

6 London Health Sciences Centre Children's Hospital, London, Ontario, Canada

7 Pediatric Parents' Advisory Group, University of Alberta, Edmonton, Canada

8 Stollery Youth Advisory Council and Patient and Family Centred Care, Edmonton, Alberta, Canada

9 Stollery Children's Hospital, Edmonton, Alberta, Canada

\*denotes corresponding author, and contact for public and scientific inquiries 3-583 Edmonton Clinic Health Academy 11405 – 87 Avenue Edmonton, AB T6G 1C9 Phone: (780) 248-5574

Phone: (780) 248-5574

Fax: (888) 775-8876

Email: sali@ualberta.ca

Keywords: virtual reality, distress, pain, distraction, pediatrics, intravenous

Trial Protocol Version 15 July 2020 Trial Registration: clinicaltrials.gov NCT04291404 WHO Trial Registration Data Set: See Table 1

Word Count: 3968/ 4000 words

Ali S, Rajagopal M, et al

#### ABSTRACT

**Introduction.** Intravenous (IV) insertions are among the most commonly performed procedures for children seeking medical care; they are often a painful and stressful experience for both children and their caregivers. Pediatric distress and pain that is inadequately treated may lead to a frightened and uncooperative child, repeated IV attempts and overall frustration with care for both the family and clinical team. We hypothesize that distraction via an immersive virtual reality (VR) experience may reduce the associated distress for children undergoing IV insertions.

#### Methods and analysis.

This two-armed randomized controlled superiority trial will be conducted in a Canadian pediatric emergency department and will aim to enroll 80 children overall. Children will be randomized to receive either departmental standard of care alone or standard of care plus an immersive VR experience. Children 6 to 17 years of age who are undergoing IV insertion and have topical anesthetic application will be considered for inclusion. Our primary objective is to compare the reduction of distress between the two study arms. The primary outcome will be the child's observed distress score as measured by the Observational Signs of Behavioral Distress-Revised (OSBD-R) tool. Secondary outcomes include the child's pain intensity and fear, parental anxiety, satisfaction with the IV procedure, as well as adverse events. Recruitment launched in September 2020 and is expected to end in January 2022.

**Ethics and dissemination.** This study has been approved by the Health Research Ethics Board (University of Alberta). Informed consent will be obtained from parents or guardians, and assent from children. Study data will be submitted for publication irrespective of results. This study is funded through a Women and Children's Health Research Institute Innovation grant. Purchase of the VR equipment was facilitated through a Stollery Children's Hospital Foundation small equipment grant.

Trial registration number: NCT04291404, First registered March 02, 2020

Words: 300/ 300

## Article Summary Strengths and limitations of this study

- 1. This randomized controlled trial will assess the effectiveness of immersive virtual reality-based distraction for the reduction of IV insertion-related distress in children.
- 2. This study measures patient- and family-relevant outcomes including child distress, pain, fear and safety as well as parental anxiety and satisfaction.
- 3. The study team includes parent and patient partners as co-investigators who will inform study methods and outcomes.
- 4. The study intervention will be compared to current standard of care; however since there is no consistent standard of care distraction practice, this may create some heterogeneity in the comparison arm of the study.
- 5. Given the nature of the study intervention, it is not possible to blind patients, parents/caregivers, health care providers, or outcome assessors; the statistician will be blinded to study arms.

## **INTRODUCTION**

Needle procedures, including venipuncture and intravenous (IV) placement, are described by children as some of the most distressing and painful parts of their healthcare visit. [1-5] Untreated distress and pain can lead to a scared and uncooperative child, a need for repeated IV attempts, reduced efficiency and overall dissatisfaction with care for the patient, family and the health care team. [4, 6, 7] Unpleasant medical encounters in childhood can also shape an individual's perception of healthcare and expectations of pain in adulthood. [4, 8-10] This can result in increased anticipatory anxiety and pain for future medical procedures or an avoidance of healthcare services, altogether. [1] As needle procedures form a routine and necessary part of care in the emergency department (ED) [11], it is an important responsibility of health care providers to adequately manage children's distress and pain, wherever possible.[12]

The recommended and responsible approach to managing children's procedural pain incorporates physical, psychological, and pharmacological components. [13-16] While pharmacological interventions such as topical anesthetic creams are available, their effectiveness is limited to *pain*, as they do not address procedure-related *distress and* anxiety. [13] Distraction therapy is a commonly employed psychological strategy which involves engaging children in a cognitive task or activity in order to divert attention away from nociceptive stimuli. [17] An effective distractor provides sensory stimulation and is highly engaging and age-appropriate in order to fully capture the attention of a child. [11] Previous research has indicated that children who use distraction as an active form of coping experience reduced pain and distress during painful procedures. [11, 18, 19] Traditional distraction techniques such as music, video, stories, imagery and focused breathing have been previously explored for children undergoing unpleasant medical procedures and demonstrated mixed results. [20-25] Our team's recently conducted systematic review of digital technologies has suggested that digital distraction techniques appear promising, but require further study to confirm their utility for painful procedures. [26]

Virtual Reality (VR) technology is rapidly emerging as a novel distraction tool for children undergoing various medical procedures. Unlike traditional distraction techniques, VR uses a combination of visual, auditory and tactile stimuli to create the illusion of being fully immersed in an artificial three-dimensional environment. [27] A Head Mounted Display (or 'VR goggles') delivers the VR video and audio to the child, and also serves to block out the view and sounds of the hospital room. [13] This further removes the patient from the chaos of the treatment room and diverts their attention away from surrounding painful and anxiety-evoking stimuli. To date, VR distraction therapy has shown promise for patients undergoing a range of distressing healthcare procedures, including burn wound cleaning, chest radiography, dental interventions and chemotherapy. [28-33] Therapeutic VR has also led to improved health outcomes for patients with anxiety disorders, phobias, post-traumatic stress disorder, and eating disorders. [34-37]

60

Due to the chaotic, noisy and unpredictable environment of the ED, it is an ideal place to 'stress-test' the ability of VR technology to immerse a child into a distracting and 'safe' space while having a medical procedure. Rapid advances in VR technology over the last few years, and improved cost-effectiveness, offers a unique opportunity to explore its use in the ED setting. While recently published studies from the ED setting suggest that there is a positive impact when VR is used for IV insertion in children, [11, 13] recent systematic reviews have concluded that the current evidence is inconclusive. [38] Furthermore, outcomes such as distress and adverse effects remain poorly studied. [38] Many previous trials utilize proprietary software designed specifically for medical use which may limit widespread accessibility to all centers. This study will evaluate an "off-the-shelf" device with a range of widely accessible software.

This study will evaluate the effectiveness of a VR intervention in reducing IV placementrelated distress for children 6-17 years old presenting to the ED. We hypothesize that the use of immersive VR distraction will reduce children's IV related distress when compared with standard of care, and will improve overall satisfaction with the procedure for the patient, family and the health care team.

## METHODS AND ANALYSIS

The Virtual Reality Study Protocol Version 1.0

This study is a two-armed, randomized, controlled superiority trial. The study protocol is reported using the SPIRIT-PRO reporting guidelines. [39] (See Table 1.)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### Table 1. WHO Trial Registration Data Set

| Data Category                  | Information   |
|--------------------------------|---|
| Primary Registry and Trial     | clinicaltrials.gov NCT04291404  |
| Identifying Number             |   |
| Date of Registration in        | March 2, 2020   |
| Primary Registry               |   |
| Secondary Identifying          | University of Alberta Research Ethics Board #   |
| Numbers                        | Pro00095418   |
| Source(s) of Monetary or       | Stollery Children's Hospital Foundation and the   |
| Material Support               | Women and Children Health Research Institute  |
|                                | Innovation Grant  |
| Primary Sponsor                | University of Alberta   |
| Secondary Sponsor(s)           | -   |
| Contact for Public Queries     | Dr. Samina Ali 780.248.5575 sali@ualberta.ca  |
| Contact for Scientific Queries | Dr. Samina Ali 780.248.5575 sali@ualberta.ca  |
| Public Title                   | The Virtual Reality Trial   |
| Scientific Title               | A randomized controlled trial of virtual reality-based  |
|                                | distraction for venipuncture-related distress in children   |
| Countries of Recruitment       | Canada  |
| Health Condition(s) or         | Venipuncture-related distress   |
| Problem(s) Studied             |   |
| Intervention(s)                | Addition of distraction via an immersive virtual reality  |
|                                | experience to departmental standard of care during the  |
|                                | intravenous (IV) insertion procedure  |
| Key Inclusion and Exclusion    | To be eligible to participate in this study, an individual  |
| Criteria                       | must meet all of the following inclusion criteria: (a)  |
|                                | child aged 6–17 years; (b) requires IV placement; and   |
|                                | (c) will receive topical anesthetic cream for IV  |
|                                | placement. Children meeting any of the following  |
|                                | criteria will be excluded: (a) medically unstable; (b)  |
|                                | unconscious or not fully alert; (c) visual, auditory  |
|                                | cognitive, or mental health issues precluding safe  |
|                                | interaction with the VR intervention; (d) conditions  |
|                                | that could be exacerbated by the VR environment,  |
|                                | such as <i>current</i> symptomatic nausea / vomiting / dizziness/migraine, or a <i>history</i> of |
|                                | psychosis/hallucinations/epilepsy; (e) presence of an   |
|                                | infection/injury which could contaminate the VR   |
|                                | intervention equipment such as open wounds/   |
|                                | infections of the head and neck area, or  |
|                                | suspected/confirmed methicillin-resistant   |
|                                | Staphylococcus aureus colonization; (f) screens   |
|                                | positive for 'influenza-like illness' as per departmental   |
|                                | screening criteria; (g) language barrier precluding the   |
|                                | ability to understand and complete study assessments,   |
| L                              |   |

|                          | in the absence of a native language translator; or (h)   |
|--------------------------|--|
|                          | previous enrollment in this study.   |
| Study Type               | Randomized Controlled Superiority Trial  |
| Date of First Enrollment | October 5, 2020  |
| Sample Size              | 80   |
| Recruitment Status       | Actively recruiting  |
| Primary Outcome(s)       | The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.   |
| Key Secondary Outcomes   | Secondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention. |
| Ethics Review            | University of Alberta Research Ethics Board #<br>Pro00095418   |
| Completion date          | -  |
| Summary Results          | -  |
| IPD sharing statement    | De-identified data can be shared, on a case-by-case basis, upon discussion with the principal investigator.  |
|                          |  |

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **Setting and Study Period**

This study will be conducted in the Stollery Children's Hospital (SCH) emergency department in Edmonton, Alberta, Canada. The SCH is a tertiary care hospital whose annual ED census is typically approximately 60,000. The 2020 ED census for the SCH was reduced to 36,899 due to the COVID-19 pandemic. Study recruitment commenced on September 28, 2020. Based on our team's previous experience conducting research in this setting, and considering the ongoing pandemic-related considerations, we anticipate 18 months of recruitment to meet our overall target of 80 patients.

#### **Eligibility and Exclusion Criteria**

Children will be eligible if they are 6 to 17 years, require an IV placement during their ED visit, and have received topical anesthetic cream for their IV placement. This age group was chosen as they are able to reliably self-report pain and are expected to benefit from the virtual reality study intervention, based on prior studies. [40] Due to ethical and pragmatic considerations, we insisted that children must be receiving topical anesthetic cream for IV placement to be eligible for our study, as it is effective and considered standard of care within our hospital. [14] Exclusion criteria are detailed in Table 1.

#### **Study Intervention and Comparison**

The intervention will include the use of an immersive VR application that will engage children for the duration of the IV procedure. The VR intervention will be provided in addition to standard of care. The child will wear the VR goggles (Oculus Ouest, Oculus, Facebook Technologies, LLC; see Figure 1) and small handheld controllers (optional) can be used to interact with the virtual environment and change settings. The VR goggles will occlude the patient's view of the treatment room, and a pair of noise-cancelling headphones (optional) can be used to block out ambient hospital sounds. Together, this will provide the child with a unique vivid experience of being fully immersed or "present" inside the 3D virtual world. The child will be presented with one of two VR menu options, one for novice users and another for more experienced users. The menus will have pre-selected VR applications that are suitable for use during the IV procedure and will include a combination of interactive games and immersive 3D movies designed specifically for a virtual reality experience (see Figure 2). The choice of applications was based on consultation with the Stollery Children's Hospital Youth Advisory Committee prior to commencing the study. The shortlisted applications were then tested by the principal investigators, other team members, and youth. The research assistant (RA), who will be trained in proper equipment use and trouble-shooting, will help the child with selecting and running the VR game/movie. Based on child and nursing preference, children may either sit up or lie in a supine position for the duration of the procedure. The chosen VR games will not require the child to move their torso or both arms, so as to not interfere with the IV placement. The VR goggles can be removed at any time during the procedure, if the child so desires.

The control group will receive departmental standard of care which will include topical anesthetic cream (mandatory for inclusion in the study) and may include parent/caregiver support, child life services, nursing support, and other support strategies at the discretion of the ED clinical care team and the family. At present, there is no single established

distraction therapy or routine that is consistently employed for IV procedures within our ED. Thus, for pragmatic and ethical considerations, it is felt that the new study VR intervention should be compared to what is currently already in practice (i.e. standard of care). Generally, VR technology is not employed by the nursing staff for distracting the child. However, other forms of technology (i.e., smart phones, tablets) will *not* be prohibited in the control group if the family chooses to offer them. Use of other devices and distraction techniques will be documented.

#### Randomization, Allocation Concealment, and Blinding

Randomization will be determined using an online randomization tool hosted on the REDCap [42] (Research Electronic Data Capture) platform. Following documentation of informed consent and assent, the RA will obtain the computer-generated randomized assignment for the child by clicking on the 'Randomize' button within the study-specific REDCap case report form. Allocation will be concealed from the research staff, ED clinical staff and the family until this point. However, due to the nature of the intervention, it is not possible to maintain blinding once the child has been randomized.

Children and their parents/caregivers will be informed that the study will evaluate and compare different forms of distraction, however they will not be made aware of the study hypothesis for the VR intervention. [7] Furthermore, the statistician will be blinded to treatment assignment by using randomization codes until data analysis is complete.

#### **Recruitment and Data Collection**

The Virtual Reality Study Protocol Version 1.0

Participant recruitment will occur in the SCH ED when RAs are on-site, from approximately 15:00 to 23:00 daily. Based on our team's previous research, this time frame corresponds with peak ED volume. RAs will screen the electronic ED track board and communicate with on-site clinical staff to identify potentially eligible patients. The RA will then further assess eligibility based on the inclusion/exclusion criteria detailed above. If the child is deemed eligible and the family is willing to participate, the RA will obtain written informed consent from the parent/ caregiver and assent from the child (See Appendix 1). One parent/caregiver for each child will be asked to provide consent and complete all relevant study questionnaires.

Prior to the beginning of the IV procedure, the RA will collect baseline information, including: baseline heart rate, pre-procedure distress, fear, and pain scores from the child, and pre-procedure anxiety score from the parent/caregiver. The RA will then access the randomization tool on REDCap to reveal the child's group assignment (VR intervention or Control).

For the VR intervention group, the RA will set up the VR equipment and spend approximately 5-10 minutes explaining the intervention to the child, including proper use of the goggles and controller. The RA will then help the child put on and secure the goggles and headphones, and hand them the controller. They will document the time required for equipment set up as well as any technical challenges encountered. As per hospital infection control policy, all VR equipment including the goggles, headphones

and controller will be sanitized with disinfectant wipes between participants. A disposable one-time use cover will be placed on the goggles for each participant. For all participants (both study arms), the RA will begin video recording the child five minutes prior to the start of the procedure and continue until 5 minutes post-procedure, to allow for complete coding of OSBD-R distress scores at a later time.

For all participants (both study arms), the staff nurse will insert the IV following institutional protocol. In keeping with the pragmatic design of the trial, no additional or study-specific instructions will be provided to either nurses or parents/caregivers regarding their behaviour during the procedure. For purposes of the study, the start of the IV insertion procedure will be marked by the cleaning of the IV site by the staff nurse. The end of the procedure will be defined by the last point of contact by the staff nurse (i.e., taping cannula in place with or without arm board, wrapping arm with gauze and taping the gauze in place).

During the procedure, the RA will closely monitor the child for any adverse effects. The child will also be asked to let the team know immediately if they are experiencing any adverse events or discomfort related to the VR intervention (i.e., dizziness, nausea, headache). The VR intervention can be discontinued (i.e., the headset can be removed) at any time, at the discretion of the child or clinical team. If an adverse event were to occur, the clinical team will be notified, and details will be logged in the REDCap adverse event log. Additionally, the RA will make a note of any technical failures or issues associated with the VR equipment during enrollment.

Immediately following the first *attempt* at IV placement (regardless of whether it was successful), the RA will collect post-procedure distress, fear and pain scores from the child, and post-procedure anxiety score from the parent/caregiver. A few minutes after completion of the IV placement, satisfaction and acceptability questionnaires will be completed with the child, parent\_caregiver as well as the staff nurse responsible for

inserting the IV. Five minutes after the procedure is completed, the RA will stop the

video recording. The duration of the procedure and total number of IV attempts will be documented. If the first attempt at placement is unsuccessful, any additional attempts will occur after all relevant study questionnaires/measurements have been completed.

Demographic information, previous history and visit details will also be collected from the family and the child's medical chart. See Figure 3 for study flow schematic.

#### **Outcome Measures**

Our primary outcome is **distress**. Our secondary outcomes are (**a**) pain; (**b**) fear; (**c**) the parental/caregiver anxiety; and (**d**) parental/caregiver and nurse satisfaction with the procedure in the intervention; and (**e**) safety.

Our primary outcome measure will be the child's total distress score during the IV procedure. Distress associated with the procedure will be assessed using the

Observational Scale of Behavioral Distress-Revised (OSBD-R). The OSBD-R is a validated scale that is widely used to measure pain and distress associated with various medical procedures in children. [43-45] The tool assesses eight specific behaviors that are indicative of distress and are weighted according to intensity: information seeking, crying, screaming, restraint, verbal resistance, emotional support, verbal pain, and flailing. Study participants will be videotaped for the duration of the IV procedure as well as for a few minutes before and after; distress will be scored pre-, during, and postprocedure. Two RAs who are trained in the use of the tool will independently observe the videotapes and record the frequency of each of the eight behaviors during continuous 15second intervals. To ensure high inter-rater reliability, the first 10% of coded videos will be analyzed for inter-rater reliability and RAs will be provided with feedback and retraining, as needed, prior to coding the remaining videos. [7] The mean OSBD-R scores between the two RAs will be used as the final scores. This standardized procedure for OSBD-R has been successfully used in previous research evaluating distraction. [30, 43, 46-49] This scale demonstrates high inter-rater reliability as well as moderate to high correlations with other behavioral measures of distress. [46, 50, 51] Our principal secondary outcome measure will be the child's pain score during the IV procedure. Pain will be measured using an 11-point verbal Numerical Rating Scale (vNRS) ranging from 0 (no pain) to 10 (worst possible pain). This scale is a commonly used pain measurement tool in pediatric acute pain studies and is validated for use in children 6-17 years of age. [52-55] Pain scores will be self-reported by children both before and immediately following the IV procedure. Fear will be measured using the Children's Fear Scale (CFS) [5, 56]. This scale depicts five faces representing increasing levels of anxiety, where the left-most face depicts "not scared at all" (score=0) and the right most-face means "most scared possible" (score=4). The CFS is an adaptation of the adult Faces Anxiety Scale [56] and has been validated to measure fear in children undergoing painful medical procedures. [5] Children will be asked to independently rate their fear both before and immediately following the IV procedure. Parental/Caregiver anxiety will be measured with the State Trait Anxiety Inventory – State Scale Revised Version (STAI-S, Form Y), a validated and commonly used version of STAI, which has improved psychometric properties. [57] Parents/caregivers will be asked to complete the STAI questionnaire both before and immediately following the IV

Parent/caregiver and nurse satisfaction with the procedure will be measured using a 5-point Likert scale, ranging from 1 "Very dissatisfied" to 5 "Very satisfied". Child satisfaction with the procedure will be measured using a 5-point Likert scale, ranging from 1 "Not at all happy" to 5 "Very happy". Satisfaction scores will be collected immediately following the IV procedure.

procedure.

Safety of the VR intervention will be determined by assessing the frequency of adverse events post intervention. Specifically, nausea will be self-rated by children immediately following the intervention, using the Baxter Retching Faces (BARF) scale [58]. This scale consists of 6 faces depicting increasing levels of nausea, with assigned scores ranging from 0 to 10. The BARF scale is widely used in medical research and has demonstrated construct, content and convergent validity as a tool to measure nausea in children. The presence of other adverse events (i.e., dizziness) will also be recorded by the RA. Children who are presenting with nausea, vomiting, dizziness or migraines *prior* to enrollment will be excluded from the study to avoid exacerbating these conditions with the use of the VR equipment.

#### Sample Size

The sample size for the study is 80 patients overall. Sample size calculations were conducted using a two-tailed, two-sample Mann-Whitney test for the primary outcome of observed behavioral distress based on data from the team's previous trial of digital distraction. To detect a large effect size of 0.6 on the OSBD-R (which was observed in a previous trial), given a Type I error of 0.05 and 80% power, the study will require 35 patients for each of the two study arms. To account for attrition and technical recording failures, the team will plan to over-recruit by 10-15%, for an overall total of 80 patients. This will allow sufficient power to find a difference in the primary outcome, if a difference truly exists.

#### **Statistical Methods**

Statistical analyses will be conducted using statistical software SAS (version 9; SAS Institute, Cary, NC). The significance level will be set at 0.05. Baseline variables will be described using appropriate summary statistics for each group. Imbalances between groups for key baseline variables will indicate the need for further adjusted analyses. For the primary outcome of observed behavioral distress, total OSBD-R scores will be compared between the two groups using independent samples t-tests if they are normally distributed or Mann-Whitney U-tests if they are skewed (the Sidak correction procedure will be used to reduce the probability of a Type I error). Additional model-based analyses (multiple linear regression) will be conducted, as needed, with behavioural distress as the response variable, pre-procedure behavioral distress and group indicators as the explanatory variables along with some possible effect modifiers such as age, sex, and parental/caregiver anxiety levels. Our primary analysis will be based on an intention-totreat approach where all children who were randomly assigned to a study group will be included in the group to which they were randomized. Where cell sizes are small or data are sparse or missing, proxy information or appropriate imputation methods will be used as needed. Similar approaches will be used to compare the groups with respect to secondary outcomes if appropriate.

#### **Patient and Public Involvement**

The team's parent advisor (KS) has provided ongoing input on the study protocol and design, and has provided valuable feedback on the content, flow and readability of the consent forms and data collection forms. The Stollery Youth Advisory Council, led by team member AP, provided input on the study design, outcomes measures, and types of

Page 13 of 53

The Virtual Reality Study Protocol Version 1.0

virtual reality applications that might be engaging and practical for our study population. AP also reviewed the study protocol and related documents to ensure that the outcomes and tools were patient-relevant and age-appropriate. Following recruitment completion, parent and youth advisors will be further engaged to discuss study results and dissemination plans in the context of patient- and family-centered care.

## Data Management and Confidentiality

Data will be entered into a secure online REDCap [42] database hosted by the Women and Children's Health Research Institute (WCHRI). (See Appendix 2 for Case Report Form.) WCHRI's REDCap installation is a validated electronic, web-based data capture system housed in a secure data center at the University of Alberta. Data is entered into REDCap through a web-based interface using 128-bit SSL encryption. Each team member will be granted an individual username/ password and will require additional two factor authentication to log in. All datasets used for statistical analysis will be encrypted and devoid of any patient identifiers. For internal data quality control, a secure master list will be maintained to accurately link study IDs to the patient's medical record.

Selected data elements will be validated electronically throughout the recruitment period and any discrepancies will be assigned to team members for timely resolution. REDCap includes internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.

Study data will be entered directly into REDCap in real-time via research iPads or, in some cases (i.e., parent/caregiver indicate a preference to complete paper-based questionnaires), responses may be collected on paper first and then transcribed into REDCap by a trained RA. All paper documents (including study questionnaires, consent/assent forms, and the master list) will be stored in a locked cabinet in a secure location that is only accessible to authorized research staff members. Study videos will be stored electronically in a secure institutional shared drive with restricted access to study staff. Videos will be stored on a secure server and computers at the University of Alberta. Following completion of the study, all data will continue to be kept in a secure location for five years as dictated by the research ethics board.

## ETHICS AND DISSEMINATION

This study has received approval from the Health Research Ethics Board (HREB) at the University of Alberta (HREB identifier: Pro00073476). Any amendments to the study protocol or documents will be submitted for HREB review and will receive approval prior to implementation. Significant protocol amendments will also be reflected online on the clinicaltrials.gov study registration. This study has also received operational approval from the SCH ED.

All children will receive the best possible care for their presenting complaint, regardless of whether they choose to participate. It is possible that patients in the VR intervention group may experience nausea, mild motion sickness or dizziness, however these effects

are rare in children and adolescents, ranging from 0-5%. [59, 60] VR applications have been selected appropriately to minimize these discomforts, and children are monitored closely throughout the study for any adverse effects. Children experiencing nausea, vomiting, dizziness or migraine headaches prior to enrollment will be excluded to avoid potential exacerbation. Study participation is unlikely to prolong the ED length of stay. For infection-control purposes, children screening positive for 'influenza-like illness' (as per ED screening criteria) are excluded to prevent potential contamination of the VR equipment.

Due to resource/logistical constraints, study recruitment will be limited to Englishspeaking families or those with their own interpreter, at a single recruiting center, and during RA shift hours only. Critically ill children requiring immediate IV insertion will also be excluded to avoid delaying medical care. This may limit the generalizability of the study findings. We will not be controlling for the type of distraction used in the standard of care arm, but we will record what was employed. While this may create some heterogeneity in the comparison arm of the study, it will be a pragmatic reflection of clinical reality. Due to the nature of the intervention, blinding is not possible for the participants or the research personnel, though the statistician will be blind to study group.

The study team plans to publish trial results in a high-impact, peer-reviewed journal and present results at national and international meetings; authorship eligibility will be determined by employing the International Committee of Medical Journal Editors' recommended guidelines. [61] Statistical code and dataset can be made available upon request.

Competing Interests None declared.

**Patient Consent** After assessing eligibility based on the outlined inclusion/exclusion criteria, research assistants will obtain consent from the parents/caregivers (and assent from children older than 6 years) prior to enrolling the child in the study. The research assistant will provide both a verbal and written explanation of the study to the family. The family will be given an opportunity to review the consent/assent forms in private and can ask the research assistant any questions they might have prior to signing the consent/assent forms. The family is free to withdraw at any point during the study.

<u>Acknowledgments</u> The authors would like to thank the members of the Stollery Youth Advisory Council, who provided valuable input on the study design and gaming/application choices for the virtual reality headsets.

## FUNDING STATEMENT

This work is funded by the generosity of the Stollery Children's Hospital Foundation through the Women and Children's Health Research Institute Innovation Grant. Purchase of the virtual reality goggles was facilitated through a generous small equipment grant

The Virtual Reality Study Protocol Version 1.0

from the Stollery Children's Hospital Foundation. The funders do not have any role in the collection, management, analysis, or interpretation of data; writing of the report; or the decision to submit the report for publication. Dr. Hartling is supported by a Canada Research Chair in Knowledge Synthesis and Translation and is a Distinguished Researchers with the Stollery Science Lab supported by the Stollery Children's Hospital Foundation.

for beer terien only

## AUTHOR CONTRIBUTIONS

Dr. Samina Ali (SA) is a pediatric emergency clinician-researcher and Professor of Pediatrics & Emergency Medicine at the University of Alberta. She co-developed and revised the protocol and co-drafted the protocol paper. She chose the previously validated tools for measuring the primary outcomes.

Manasi Rajagopal (MR) is the program lead for the Pediatric Emergency Medicine research program at the University of Alberta and co-principal investigator of this study. She co-developed the study protocol, co-drafted the protocol paper, and will operationalize the study.

Dr. Jennifer Stinson (JS) is the Mary Jo Haddad Nursing Chair in Child Health at the Hospital for Sick Children's Research Institute and a nurse practitioner in the Department of Anesthesia's chronic pain program at the hospital. She assisted with the study design and protocol revision.

Dr. Keon Ma is a pediatric trainee at the University of Calgary, with expertise in OSBD-R coding. He assisted with the study design and protocol revision.

Ben Vandermeer (BV) led the statistical analysis planning and contributed to protocol revision.

Bailey Felkar (BF) is a child life specialist at the Stollery ED with expertise in managing children's pain and distress in the ED setting. She assisted with the study design and protocol revision.

Kurt Schreiner (KS) is a family partner who has provided input into study outcomes to ensure family-relevant outcomes are chosen and will inform our knowledge translation efforts to the public.

Amanda Proctor (AP) is the coordinator of the Stollery Youth Advisory Council. Together with the council, she informed programming choices for the virtual reality devices and has reviewed the protocol and related documents to ensure that the outcomes and tools are patient-relevant and age-appropriate.

Jennifer Plume (JP) is the acting director for Stollery child life services with expertise in managing children's pain and distress in the ED. She has informed study methods and will aid and support the development of our knowledge translation plan.

Dr. Lisa Hartling (LH) is a Professor in the Department of Pediatrics at the University of Alberta and Director of the Alberta Research Centre for Health Evidence (Edmonton, Canada). She assisted with the study design and drafting the protocol, and provides expertise in clinical trial methodology and statistical analyses.

The Virtual Reality Study Protocol Version 1.0

All authors have approved this final version of the protocol. None of the authors have financial or other conflicts of interests as they pertain to this study and its involved recruitment sites.

For beer terien only

## **Figures Legend**

**Figure 1.** Child using virtual reality goggles in the emergency department **Figure 2.** Virtual Reality Game Menus **Figure 3.** Flow Diagram of Study Procedures

tor peer teriew only

The Virtual Reality Study Protocol Version 1.0

#### REFERENCES

- 1. Atzori B, Hoffman HG, Vagnoli L, et al. Virtual Reality Analgesia During Venipuncture in Pediatric Patients With Onco-Hematological Diseases, *Front Psychol* 2018;9 doi:10.3389/fpsyg.2018.02508.
- 2. Duff AJA. Incorporating psychological approaches into routine paediatric venepuncture, *Archives of Disease in Childhood* 2003;88:931-7 doi:10.1136/adc.88.10.931.
- 3. Caprilli S, Messeri A. Animal-Assisted Activity at A. Meyer Children's Hospital: A Pilot Study, *Evidence-based Complementary and Alternative Medicine* 2006;3:379 doi:10.1093/ecam/nel029.
- 4. Sanchez Cristal N, Staab J, Chatham R, et al. Child Life Reduces Distress and Pain and Improves Family Satisfaction in the Pediatric Emergency Department, *Clin Pediatr (Phila)* 2018;57:1567-75 doi:10.1177/0009922818798386.
- McMurtry CM, Noel M, Chambers CT, et al. Children's fear during procedural pain: Preliminary investigation of the Children's Fear Scale, *Health Psychology* 2011;30:780-8 doi:10.1037/a0024817.
- 6. McGrath PJ, McAlpine L. Psychologic perspectives on pediatric pain, *The Journal of Pediatrics* 1993;122:S2-8 doi:10.1016/S0022-3476(11)80002-8.
- 7. Ali S, Sivakumar M, Beran T, et al. Study protocol for a randomised controlled trial of humanoid robot-based distraction for venipuncture pain in children, *BMJ Open* 2018;8:e023366 doi:10.1136/bmjopen-2018-023366.
- 8. El-Housseiny AA, Alamoudi NM, Farsi NM, et al. Characteristics of dental fear among Arabic-speaking children: a descriptive study, *BMC Oral Health* 2014;14 doi:10.1186/1472-6831-14-118.
- 9. Fields H. How expectations influence pain, *Pain* 2018;159:S3-S10 doi:10.1097/j.pain.00000000001272.
- 10. Noel M, Rabbitts JA, Tai GG, et al. Remembering Pain after Surgery: A Longitudinal Examination of the Role of Pain Catastrophizing in Children's and Parents' Recall, *Pain* 2015;156:800 doi:10.1097/j.pain.00000000000102.
- 11. Dumoulin S, Bouchard S, Ellis J, et al. A Randomized Controlled Trial on the Use of Virtual Reality for Needle-Related Procedures in Children and Adolescents in the Emergency Department. , *Games for Health Journal* 2019;8:285-93.
- 12. Jain S, Hegenbarth MA, Humiston SG, et al. Increasing ED use of jet injection of lidocaine for IV-related pain management , *Pediatrics* 2017;139:e20161697.
- 13. Chan E, Hovenden M, Ramage E, et al. Virtual Reality for Pediatric Needle Procedural Pain: Two Randomized Clinical Trials, *The Journal of Pediatrics* 2019;209:160,167.e4 doi:10.1016/j.jpeds.2019.02.034.
- Trottier ED, Doré-Bergeron MJ, Chauvin-Kimoff L, et al. Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures. [CPS Position Statement], *Paediatrics & Child Health* 2019;24:509-21.
- 15. Friedrichsdorf SJ, Eull D, Weidner CA. A Children's Comfort Promise: how can we do everything possible to prevent and treat pain in children using quality improvement strategies? *Pediatric Pain Letter* 2016;18:26-30.
- 16. Gaskell S. Evidence-based guidelines for the management of invasive and/or distressing procedures with children, *British Journal of Social Psychology* 2019.

- The Virtual Reality Study Protocol Version 1.0
- 17. McCaul KD, Malott JM. Distraction and coping with pain, Pain 1985;23:315.
- 18. Manne SL, Bakeman R, Jacobsen PB, et al. An analysis of a behavioral intervention for children undergoing venipuncture, *Health Psychology* 1994;13:556-66.
- 19. Vessey JA, Carlson KL, McGill J. Use of distraction with children during an acute pain experience, *Nursing Research* 1994;43:369-72 doi:10.1097/00006199-199411000-00009.
- 20. Klassen JA, Liang Y, Tjosvold L, et al. Music for Pain and Anxiety in Children Undergoing Medical Procedures: A Systematic Review of Randomized Controlled Trials, *Ambulatory Pediatrics* 2008;8:117-28 doi:10.1016/j.ambp.2007.12.005.
- 21. Cohen LL, Blount RL, Panopoulos G. Nurse Coaching and Cartoon Distraction: An Efective and Practical Intervention to Reduce Child, Parent, and Nurse Distress During Immunizations, *J Pediatr Psychol* 1997;22:355-70 doi:10.1093/jpepsy/22.3.355.
- 22. Cassidy K, Reid GJ, McGrath PJ, et al. Watch Needle, Watch TV: Audiovisual Distraction in Preschool Immunization, *Pain Med* 2002;3:108-18 doi:10.1046/j.1526-4637.2002.02027.x.
- 23. Downey LVA, Zun LS. The Impact of Watching Cartoons for Distraction During Painful Procedures in the Emergency Department, *Pediatric Emergency Care* 2012;28:1033 doi:10.1097/PEC.0b013e31826cac1a.
- 24. Young T, Griffin E, Phillips E, et al. Music as Distraction in a Pediatric Emergency Department, *Journal of Emergency Nursing* 2010;36:472-3 doi:10.1016/j.jen.2010.05.014.
- 25. Ha YO, Kim HS. The effects of audiovisual distraction on children's pain during laceration repair, *International Journal of Nursing Practice* 2013;19:20-7 doi:10.1111/ijn.12165.
- 26. Gates M, Hartling L, Shulhan-Kilroy J, et al. Digital Technology Distraction for Acute Pain in Children: A Meta-analysis, *Pediatrics* 2020;145 doi:10.1542/peds.2019-1139.
- 27. Ahmadpour N, Randall H, Choksi H, et al. international journal of biochemistry & cell biology, 2019;114:105568.
- 28. Sikka N, Shu L, Ritchie B, et al. Virtual Reality-Assisted Pain, Anxiety, and Anger Management in the Emergency Department, *Telemedicine and e-Health* 2019.
- 29. Hoffman HG, Doctor JN, Patterson DR, et al. Use of virtual reality for adjunctive treatment of adolescent burn pain during wound care: A case report, *Pain* 2000;1-2:305-9.
- 30. Han S, Park J, Choi SI, et al. Effect of Immersive Virtual Reality Education Before Chest Radiography on Anxiety and Distress Among Pediatric Patients: A Randomized Clinical Trial, *JAMA pediatrics* 2019 doi:10.1001/jamapediatrics.2019.3000.
- 31. Shetty V, Suresh LR, Hegde AM. Effect of Virtual Reality Distraction on Pain and Anxiety During Dental Treatment in 5 to 8 Year Old Children, *Journal of Clinical Pediatric Dentistry* 2019;43:97-102.
- 32. Furman E, Jasinevicius TR, Bissada NF, et al. Virtual Reality Distraction for Pain Control During Periodontal Scaling and Root Planing Procedures, *The Journal of the American Dental Association* 2009;140:1508-16 doi:10.14219/jada.archive.2009.0102.


- 33. Schneider SM, Hood LE. Virtual Reality: A Distraction Intervention for Chemotherapy, *Oncology nursing forum* 2007;34:39-46 doi:10.1188/07.ONF.39-46.
- 34. Gerardi M, Rothbaum BO, Ressler K, et al. Virtual reality exposure therapy using a virtual Iraq: Case report, *Journal of Traumatic Stress* 2008;21:209-13 doi:10.1002/jts.20331.
- 35. Parsons TD, Rizzo AA. Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: A meta-analysis, *Journal of Behavior Therapy and Experimental Psychiatry* 2008;39:250-61 doi:10.1016/j.jbtep.2007.07.007.
- 36. Botella C, Serrano B, Baños RM, et al. Virtual reality exposure-based therapy for the treatment of post-traumatic stress disorder: a review of its efficacy, the adequacy of the treatment protocol, and its acceptability, *Neuropsychiatr Dis Treat* 2015;11:2533-45 doi:10.2147/NDT.S89542.
- 37. Marco JH, Perpiñá C, Botella C. Effectiveness of cognitive behavioral therapy supported by virtual reality in the treatment of body image in eating disorders: One year follow-up, *Psychiatry Research* 2013;209:619-25 doi:10.1016/j.psychres.2013.02.023.
- Lambert V, Boylan P, Boran L, et al. Virtual reality distraction for acute pain in children, *The Cochrane database of systematic reviews* 2020;10 doi:10.1002/14651858.CD010686.pub2.
- 39. Chan A, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials, *Ann Intern Med* 2013;158:200-7 doi:10.7326/0003-4819-158-3-201302050-00583.
- 40. Hoffman HG, Rodriguez RA, Gonzalez M, et al. Immersive Virtual Reality as an Adjunctive Non-opioid Analgesic for Pre-dominantly Latin American Children With Large Severe Burn Wounds During Burn Wound Cleaning in the Intensive Care Unit: A Pilot Study, *Frontiers in human neuroscience* 2019;13 doi:10.3389/fnhum.2019.00262.
- 41. Gouin S, Gravel J, Amre DK, et al. Evaluation of the Paediatric Canadian Triage and Acuity Scale in a pediatric ED, *Am J Emerg Med* 2005;23:243-7 doi:10.1016/j.ajem.2004.02.046.
- 42. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support, *Journal of Biomedical Informatics* 2009;42:377-81 doi:10.1016/j.jbi.2008.08.010.
- 43. Jay SM, Elliott C. Observation Scale of Behavioral Distress-Revised. Information procedures, definitions of behaviors, OSBD Interval Coding Form. 1986.
- 44. Jay SM, Elliott C. Behavioral observation scales for measuring children's distress: The effects of increased methodological rigor, *Journal of Consulting and Clinical Psychology* 1984;52:1106-7 doi:10.1037/0022-006X.52.6.1106.
- Tucker CL, Slifer KJ, Dahlquist LM. Reliability and Validity of the Brief Behavioral Distress Scale: A Measure of Children's Distress During Invasive Medical Procedures, *J Pediatr Psychol* 2001;26:513-23 doi:10.1093/jpepsy/26.8.513.
- Elliott CH, Jay SM, Woody P. An Observation Scale for Measuring Children's Distress During Medical Procedures, *J Pediatr Psychol* 1987;12:543-51 doi:10.1093/jpepsy/12.4.543.

The Virtual Reality Study Protocol Version 1.0

47. Megel ME, Houser CW, Gleaves LS. Children's Responses to Immunizations: Lullabies as a Distraction, *Issues in Comprehensive Pediatric Nursing* 1998;21:129-45 doi:10.1080/014608698265456.

- Noguchi LK. The Effect of Music Versus Nonmusic on Behavioral Signs of Distress and Self-Report of Pain in Pediatric Injection Patients, *J Music Ther* 2006;43:16-38 doi:10.1093/jmt/43.1.16.
- 49. Hartling L, Newton AS, Liang Y, et al. Music to Reduce Pain and Distress in the Pediatric Emergency Department: A Randomized Clinical Trial, *JAMA Pediatrics* 2013;167:826-35 doi:10.1001/jamapediatrics.2013.200.
- 50. Stevenson MD, Bivins CM, O'Brien K, et al. Child Life Intervention During Angiocatheter Insertion in the Pediatric Emergency Department, *Pediatric Emergency Care* 2005;21:712 doi:10.1097/01.pec.0000186423.84764.5a.
- Jay SM, Ozolins M, Elliott CH, et al. Assessment of children's distress during painful medical procedures, *Health Psychology* 1983;2:133-47 doi:10.1037/0278-6133.2.2.133.
- 52. von Baeyer CL. Children's self-report of pain intensity: what we know, where we are headed, *Pain research & management* 2009;14:39.
- 53. Miró J, Castarlenas E, de la Vega R, et al. Validity of three rating scales for measuring pain intensity in youths with physical disabilities, *Eur J Pain* 2016;20:130-7 doi:10.1002/ejp.704.
- 54. Castarlenas E, Jensen MP, von Baeyer CL, et al. Psychometric Properties of the Numerical Rating Scale to Assess Self-Reported Pain Intensity in Children and Adolescents: A Systematic Review, *Clin J Pain* 2017;33:376-83 doi:10.1097/AJP.00000000000406.
- 55. Castarlenas E, Miró J, Sánchez-Rodríguez E. Is the verbal numerical rating scale a valid tool for assessing pain intensity in children below 8 years of age? *J Pain* 2013;14:297-304 doi:10.1016/j.jpain.2012.12.004.
- 56. McKinley S, Coote K, Stein-Parbury J. Development and testing of a Faces Scale for the assessment of anxiety in critically ill patients, *Journal of Advanced Nursing* 2003;41:73-9 doi:10.1046/j.1365-2648.2003.02508.x.
- 57. Spielberger CD, Sydeman SJ. State-trait anxiety inventory and state-trait anger expression inventory. Hillsdale, NJ: Lawrence Erlbaum Associates 1994:292-321.
- 58. Baxter AL, Watcha MF, Baxter WV, et al. Development and validation of a pictorial nausea rating scale for children. *Pediatrics* 2011;127:1542.
- 59. Gold JI, Mahrer NE. Is Virtual Reality Ready for Prime Time in the Medical Space? A Randomized Control Trial of Pediatric Virtual Reality for Acute Procedural Pain Management, *Journal of pediatric psychology* 2018;43 doi:10.1093/jpepsy/jsx129.
- 60. Hoffman HG, Patterson DR, Seibel E, et al. Virtual reality pain control during burn wound debridement in the hydrotank, *The Clinical journal of pain* 2008;24 doi:10.1097/AJP.0b013e318164d2cc.
- 61. ICMJE. International Committee of Medical Journal Editors. 2017. Available: <u>http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html</u> [Accessed 03 Aug 2021].







#### A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date               |
|--------------------|--------------|------------------------------|
| PI: Dr. Samina Ali | VR           | // <u>2 0</u><br>dd mmm yyyy |

## **Pre-Screening**

| Date and Time of Triage                   | //<br>dd mmm yyyy<br>:<br>(24 hour clock)  |
|---|--|
| Child's Age                               | years  |
| Child's Sex                               | Female Male  |
| Was the family approached for this study? | Yes No   |
| If NO, specify reason and STOP HERE.      | <ul> <li>Family refused overall consent to be approached for research</li> <li>Legal guardian not present</li> <li>RA busy with another study</li> <li>Did not meet eligibility criteria, specify</li> <li>Other, Specify</li> </ul> |
| If YES, continue to Eligibility.          | 2  |



#### 

| A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: |
|---|
| The VR Study  |

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

## Eligibility

| Was verbal consent for screening obtained from the fam | ilv? | es 🗌 No |
|--|------|---------|
|  |      |         |

## **Inclusion Criteria**

| 1. Child aged 6-17 years                                  | 🗌 Yes | 🗌 No |  |  |  |
|---|-------|------|--|--|--|
| 2. Requires IV placement                                  | 🗌 Yes | 🗌 No |  |  |  |
| 3. Will receive topical anesthetic cream for IV placement | 🗌 Yes | 🗌 No |  |  |  |
|   |       |      |  |  |  |
| Exclusion Criteria  |       |      |  |  |  |

## **Exclusion Criteria**

| 1.    | Medically unstable (i.e. CTAS 1, requires immediate IV insertion)  | 🗌 Yes | 🗌 No |
|-------|--|-------|------|
| 2.    | Unconscious or not fully alert   | 🗌 Yes | 🗌 No |
| 3.    | Visual, auditory or cognitive or mental health issues precluding safe interaction with the VR intervention   | 🗌 Yes | 🗌 No |
| 4.    | Conditions that could be exacerbated by the VR environment (as reported by the family)<br>a. <i>current</i> symptomatic nausea / vomiting / dizziness / migraine<br>b. <i>history</i> of psychosis / hallucinations / epilepsy   | 🗌 Yes | 🗌 No |
| 5.    | Presence of an infection / injury which could contaminate the VR intervention<br>equipment (as determined by the healthcare team) including but not limited to<br>a. open wounds / infections of the head and neck area<br>b. suspected or confirmed methicillin-resistant <i>Staphylococcus aureus</i><br>(MRSA) colonization | 🗌 Yes | No   |
| 6.    | Screens positive for 'influenza-like illness' (ILI) as per the current SCH ED screening criteria   | 🗌 Yes | 🗌 No |
| 7.    | Child or Parental language barrier precluding the ability to understand and complete study assessments, in the absence of a native language translator   | 🗌 Yes | 🗌 No |
| 8.    | Previous enrollment (of child OR parent) in this study   | 🗌 Yes | 🗌 No |
| ls th | ne family eligible for the study?  | 🗌 Yes | 🗌 No |



| REB #: Pro00095418  | Screening ID  | Enrolment Date  |
|---|---|---|
| PI: Dr. Samina Ali  | VR  | // <u>2 0</u><br>dd mmm yyyy                                  |
| nformed Consent   |   |   |
|   | t been obtained from the parent/ legal o  | juardian? 🔄 Yes 🛄 I   |
| <u>NO,</u>  | <u> </u>  |   |
| Specify reason and STOP I   | HERE.   | <ul> <li>Declined consent</li> <li>Declined assent</li> </ul> |
|   |   | Other, please specify   |
|   | R   |   |
| <u>YES</u> ,  | <u>`</u>  |   |
| Specify the date and time o                                       | f Informed Consent  | //<br>dd mmm yyyy   |
|   |   | ;   |
|   |   | (24 hour clock)   |
| Has a copy of the signed inf                                      | ormed consent been given to the family?   | ☐ Yes   |
|   |   | □ No; specify:  |
| Has written assent been ob  | tained from the child?  | Yes   |
|   |   | No; specify:  |
|   |   | No, but verbal assent was obtained and documented             |
|   |   | □ Not required; child < 7y                                    |
| Has a conv of the signed as                                       | ssent been given to the family?   |   |
|   |   | ☐ No; specify:  |
| Has written informed conse  | nt been provided by the clinical nurse?   |   |
| Note: Consent only needs to b<br>entire duration of the study (fo | be provided by the clinical nurse once for the<br>or all 80-90 participants). If consent has not<br>h the clinical nurse, make sure a signed copy | ☐ No; specify:  |
| Clinical Nurse Study ID Nur                                       |   |   |





A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

## Randomization

If the child satisfies the inclusion/ exclusion criteria and written informed consent has been provided, please RANDOMIZE the participant by clicking on the Randomize button below:

| Study Arm | <ul><li>VR Intervention</li><li>Standard Care</li></ul> |
|-----------|---|
|           |   |
|           |   |
|           |   |
|           |   |
|           |   |
|           |   |
|           |   |
|           |   |
|           |   |
|           |   |
|           |   |
|           |   |
|           |   |



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date            |
|--------------------|--------------|---------------------------|
| PI: Dr. Samina Ali | VR           | // <u>20</u><br>ddmmmyyyy |

## **Demographics & History**

### **Demographics**

| Parent/ Caregiver relationship to child                       | Mother                           |
|---|----------------------------------|
|   | Father                           |
|   | Other; specify:                  |
| Parent / Caregiver Age  | years; or 🗌 Prefer not to answer |
| Parent / Caregiver Sex  | E Female                         |
|   | Male                             |
| Parent / Caregiver Highest level of Education                 | Elementary School                |
|   | High School or some High School  |
|   | Diploma/ Certificate             |
|   | Some Post-Secondary/ University  |
|   | University/ Professional Degree  |
|   | Decline to answer                |
| First three digits of postal code                             | (1 <sup>st</sup> 3 digits ONLY)  |
| Do you identify your child as a member of an ethnic minority? | Yes                              |
|   | No                               |
| · L   | )                                |
| Medical History   |                                  |

## **Medical History**

| Was your child born prematurely?                            | Yes   |
|---|-------|
|   | No    |
| If yes, at how many weeks gestation?                        | weeks |
| Has your child ever been to the Emergency Department before | ☐ Yes |
| today?  | 🗌 No  |
| If yes, how many times:                                     | times |
| Has your child ever been hospitalized?                      | ☐ Yes |
|   | 🗌 No  |
| If yes, how many times:                                     | times |
| Has your child ever had a needle poke in their vein to draw | ☐ Yes |
| blood or put in an intravenous (IV) line?                   | 🗌 No  |



| REB #: Pro00095418   | Screening ID                  |   |                | Enrolment Date                |
|--|-------------------------------|---|----------------|-------------------------------|
| PI: Dr. Samina Ali   | VR                            |   |                | / / <u>2 0</u><br>dd mmm yyyy |
| If yes, how distressed wa  | s your child during the proc  | cedure? (if                               | 🗌 1 (no dis    | stress at all)                |
| more than one occurrenc  | e, ask the parent to recall t | he most                                   | □ 2            |                               |
| <i>recent event)</i> Choose a r  | umber between 1 and 5 th      | at best                                   | <br>□ 3        |                               |
| describes your child's dis   | tress where 1 indicates 'no   | distress at                               |                |                               |
| all' and 5 is 'as distressed   | d as possible'                |   |                | tressed as possible)          |
| Child Experience with<br>Has your child played wit<br>following devices before | h/ used any of the            |   |                | ablet <i>(to play games)</i>  |
| following devices before   | to <b>play games</b> ?        | Gaming                                    | console        |                               |
|  |                               | (ex. Xbox                                 | k, Nintendo, P | S4, other)                    |
|  |                               | ☐ Virtual Reality (VR) device             |                |                               |
|  |                               | (ex. Oculus Quest/ Rift, Samsung Gear VR, |                |                               |
|  |                               | HTC Vive, PlayStation VR, other)          |                |                               |
|  |                               | Robot                                     |                |                               |
| If yes, how frequently?  |                               | 1   |                |                               |
| iPad/ iPod/ iPhone /<br>Tablet:  | Gaming console                | VR d                                      | evice          | Robot                         |
| hours/ week  | hours/ week                   | h h                                       | ours/ week     | hours/ week                   |
| Less than Once per   | Less than Once per            | Less tha                                  |                | Less than Once per            |
| week   | week                          | week                                      |                | week                          |
| Less than 5 times in   | Less than 5 times in          | Less tha                                  | n 5 times in   | Less than 5 times in          |
| total  | total total                   |   |                | total                         |
| Other, specify   | Other, specify Other, spe     |   | pecify         | Other, specify                |
|  |                               |   |                |                               |
|  |                               |   |                |                               |
|  |                               |   |                |                               |
|  |                               |   |                |                               |
|  |                               |   |                |                               |

VR Study CRF



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date              |
|--------------------|--------------|-----------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>ddmmmyyyy |


## **PRE-Procedure: Child Scores**

NOTE: Begin the video recorder (iPad) approximately 5 minutes before the start of the IV procedure, and stop the recording 5 minutes after the end of the procedure.

## **Baseline Scores: Child**

| Heart Rate (record from Triage)  | bpr  | n                          |       |
|--|------|----------------------------|-------|
| Time pre-procedure scores collected  | dd   | /<br>mmm<br>:<br>ur clock) | /<br> |
| Pain Score: verbal Numerical Rating Scale (vNRS)<br>"On a scale of 0 to 10, where 0 is no pain and 10 is the worst<br>pain you can imagine, what is your pain level now?"            | / 10 | ,                          |       |
| Distress Score: Numerical Rating Scale<br>"On a scale of 0 to 10, where 0 is no distress and 10 is the<br>most distress you can imagine having, what is your distress<br>level now?" | / 10 | D                          |       |

"These faces are showing different amounts of being scared. This face [point to the left-most face] is not scared at all, this face is a little bit more scared [point to the second face from left], a bit more scared [sweep finger along scale], right up to the most scared possible [pint to the last face on the right]. Have a look at these faces and choose the one that shows how scared you are right now."







A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

## PRE-Procedure: Parent / Caregiver STAI Questionnaire

We would ask that you complete the following questions as they relate to your feelings about your child's upcoming IV procedure, today. A number of statements which people have used to describe themselves are given below. Read each statement and then circle the appropriate number to indicate how you feel right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time on any one statement but give the answer which seems to describe your feelings best.

| 18       |     |   |   |   |   |   |
|----------|-----|---|---|---|---|---|
| 19       |     | 14  |   |   |   |   |
| 20       |     | Not at all Somewhat Moderately so Very much so    |   |   |   |   |
| 21       |     |   |   |   |   |   |
| 22<br>23 | 1.  | I feel calm                                       | 1 | 2 | 3 | 4 |
| 24<br>25 | 2.  | I feel secure                                     | 1 | 2 | 3 | 4 |
| 25<br>26 | 3.  | I am tense  | 1 | 2 | 3 | 4 |
| 27<br>28 | 4.  | I feel strained                                   | 1 | 2 | 3 | 4 |
| 29       | 5.  | I feel at ease                                    | 1 | 2 | 3 | 4 |
| 30<br>31 | 6.  | I feel upset                                      | 1 | 2 | 3 | 4 |
| 32<br>33 | 7.  | I am presently worrying over possible misfortunes | 1 | 2 | 3 | 4 |
| 34       | 8.  | I feel satisfied                                  | 1 | 2 | 3 | 4 |
| 35<br>36 | 9.  | I feel frightened                                 | 1 | 2 | 3 | 4 |
| 37<br>38 | 10. | I feel comfortable                                | 1 | 2 | 3 | 4 |
| 39       | 11. | I feel self-confident                             | 1 | 2 | 3 | 4 |
| 40<br>41 | 12. | I feel nervous                                    | 1 | 2 | 3 | 4 |
| 42<br>43 | 13. | I am jittery                                      | 1 | 2 | 3 | 4 |
| 43<br>44 | 14. | I feel indecisive                                 | 1 | 2 | 3 | 4 |
| 45<br>46 | 15. | I am relaxed                                      | 1 | 2 | 3 | 4 |
| 47<br>48 | 16. | I feel content                                    | 1 | 2 | 3 | 4 |
| 48<br>49 | 17. | I am worried                                      | 1 | 2 | 3 | 4 |
| 50<br>51 | 18. | I feel confused                                   | 1 | 2 | 3 | 4 |
| 52       | 19. | I feel steady                                     | 1 | 2 | 3 | 4 |
| 53<br>54 | 20. | I feel pleasant                                   | 1 | 2 | 3 | 4 |
| 55       |     |   |   |   |   |   |



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date            |
|--------------------|--------------|---------------------------|
| PI: Dr. Samina Ali | VR           | // <u>20</u><br>ddmmmyyyy |

## **DURING-Procedure**

- Start the iPad video recording approximately 5 minutes prior to the start of the procedure.
- For children randomized to the VR group: Immediately after PRE-procedure scores and STAI are completed, research assistant will set up the VR equipment.
- The staff ED nurse will then begin the IV set-up

| Start time of IV procedure:   |       | _/               | _/        |
|---|-------|------------------|-----------|
| (Defined as the time the staff nurse begins to clean the IV site)   | dd    | mmm              | уууу      |
| $\mathbf{O}$  | (24 h | _:<br>our clock) |           |
| End time of IV procedure/ attempt:  | ,     | ,                |           |
| (Defined as the last point of contact by the staff nurse (ex. taping<br>cannula in place with or without arm board, wrapping arm with<br>gauze and taping the gauze in place) | dd    | _/<br>mmm<br>:   | /<br>уууу |
|   | (24 h | our clock)       |           |

| Position of Child during IV attempt:  | Sitting up Lying down (supine)  |  |  |
|---|---|--|--|
| Location of first IV attempt:   | <ul> <li>Antecubital Fossa – RIGHT</li> <li>Antecubital Fossa – RIGHT</li> <li>Dorsum hand – RIGHT</li> <li>Dorsum hand – LEFT</li> <li>Other, specify</li> </ul> |  |  |
| Was the first IV placement attempt successful?  |   |  |  |
| <ul> <li>If NO, how many attempts, in total, were made for the<br/>IV during this 'episode'?</li> </ul> | attempts  |  |  |
| Was an IV successfully placed during this 'episode'?  | Yes No  |  |  |

| Any adverse events or side effects?  | Yes No  |
|--|---|
| Do not suggest any AEs to the participant; Instead, ask more general questions such as "how are you feeling?" or "are you having any side effects?" or "are you feeling any different than before?", and let the child answer spontaneously. | If " <b>YES</b> ", complete a separate entry for each AE on the AE Form |



| REB #: Pro00095418   |   | Screening ID  |  | Enrolment Date   |
|--|---|---|--|--|
| PI: Dr. Samina Ali   | VR  |   |  | // <u>2</u> 0/<br>dd mmm yyyy  |
| <b>IMEDIATELY PO</b><br>OTE: Post-procedure so<br>ocedure is complete:                             | cores/ questionnair   |   | -  | <u>possible</u> after the  |
| ost-procedure Score  | es: Child   |   |  |  |
| Time post-procedure sc   | ores collected  |   |  | dd mmm yyyy  |
|  | 0   |   |  | ::<br>(24 hour clock)  |
| Pain Score: verbal Num<br>'On a scale of 0 to 10, v<br>magine, what was your                       | where 0 is no pain a  | and 10 is the wors  | t pain you can                                       | / 10   |
| Distress Score: Numerie<br>"On a scale of 0 to 10, v<br>you can imagine having<br><u>IV poke</u> " | where 0 is no distre  | ess and 10 is the r   |  | / 10   |
| scared at all, this face is<br>[sweep finger along sca   | ng different amoun<br>s a little bit more sc<br>le], right up to the r                      | ts of being scared<br>ared [point to the<br>most scared possi | second face from<br>ole [pint to the la              | to the left-most face] is not<br>in left], a bit more scared<br>ist face on the right]. Have<br>ing the needle / IV poke." |
|  |   |   |  |  |
| call that feeling of being<br>all, who feel a little bit n   | felt like you were g<br>sick to the stomac<br>auseated, who feel<br>ble to feel." [Point to | joing to throw up b<br>h nausea. These<br>even more nause     | efore? How did<br>aces show child<br>ated, and these | your tummy feel then? We<br>ren who feel no nausea at<br>are children who have the<br>.] "Which face is more like          |



| REB #: Pro00095418       | Screening ID   | Enrolment Date  |
|--------------------------|--|---|
| PI: Dr. Samina Ali       | VR   | / / <u>2 0</u><br>dd mmmyyyy  |
|                          |  |   |
|                          |  |   |
| · · · · · ·              | vere you with the IV start today, on a scale of 1<br>at all happy" and 5 means "Very happy"?         | to 5,<br>1 "Not at all happy<br>2<br>3<br>4<br>5 "Very happy"   |
|                          | where 1 means "Not at all happy" and 5 means appy were you <u>with the pain treatment</u> for your I | <ul> <li>✓ 1 "Not at all happy"</li> <li>✓ 2</li> <li>✓ 3</li> <li>✓ 4</li> <li>✓ 5 "Very happy"</li> </ul> |
| Did the [distraction / t | toys / VR goggles] help you today?   | Yes, it helped         No, it didn't help         'm not sure   |
|                          | t an IV or needle poke again, would you want to<br>/ toys / VR goggles] again?                       | use<br>Yes, I would<br>No, I wouldn't<br>I'm not sure   |
| Con you toll n           | ne why/ why not?   |   |

As soon as possible after completion of procedure, research assistant to give:

1. Post-Procedure Parent STAI and Satisfaction Questionnaire to parent/ caregiver

2. Nurse Satisfaction Questionnaire to staff ED nurse





 A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VP Study

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# **POST-Procedure:** Parent / Caregiver STAI Questionnaire

We would ask that you complete the following questions as they relate to your feelings about your child's IV procedure that just happened. A number of statements which people have used to describe themselves are given below. Read each statement and then circle the appropriate number to indicate how you feel right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time on any one statement but give the answer which seems to describe your feelings best.

| 10       |     | 13   |   |   |   |   |
|----------|-----|--|---|---|---|---|
| 19<br>20 |     | I4<br>Not at all Somewhat Moderately so Very much so |   |   |   |   |
| 20       |     |  |   |   |   |   |
| 22<br>23 | 1.  | I feel calm  | 1 | 2 | 3 | 4 |
| 24       | 2.  | I feel secure  | 1 | 2 | 3 | 4 |
| 25<br>26 | 3.  | I am tense   | 1 | 2 | 3 | 4 |
| 27<br>28 | 4.  | I feel strained                                      | 1 | 2 | 3 | 4 |
| 29<br>30 | 5.  | I feel at ease                                       | 1 | 2 | 3 | 4 |
| 31       | 6.  | I feel upset   | 1 | 2 | 3 | 4 |
| 32<br>33 | 7.  | I am presently worrying over possible misfortunes    | 1 | 2 | 3 | 4 |
| 34<br>35 | 8.  | I feel satisfied                                     | 1 | 2 | 3 | 4 |
| 36       | 9.  | I feel frightened                                    | 1 | 2 | 3 | 4 |
| 37<br>38 | 10. | I feel comfortable                                   | 1 | 2 | 3 | 4 |
| 39<br>40 | 11. | I feel self-confident                                | 1 | 2 | 3 | 4 |
| 41       | 12. | I feel nervous                                       | 1 | 2 | 3 | 4 |
| 42<br>43 | 13. | I am jittery   | 1 | 2 | 3 | 4 |
| 44<br>45 | 14. | I feel indecisive                                    | 1 | 2 | 3 | 4 |
| 46       | 15. | I am relaxed   | 1 | 2 | 3 | 4 |
| 47<br>48 | 16. | I feel content                                       | 1 | 2 | 3 | 4 |
| 49<br>50 | 17. | I am worried   | 1 | 2 | 3 | 4 |
| 51       | 18. | I feel confused                                      | 1 | 2 | 3 | 4 |
| 52<br>53 | 19. | I feel steady  | 1 | 2 | 3 | 4 |
| 54<br>55 | 20. | I feel pleasant                                      | 1 | 2 | 3 | 4 |



| REB #: Pro00095418            |                            | Screening ID                           |                       | Enrolment Date             |  |
|-------------------------------|----------------------------|--|-----------------------|----------------------------|--|
| PI: Dr. Samina Ali            | Dr. Samina Ali VR          |  | -                     | // <u>2</u> 0<br>dd mmm yy |  |
| OST-Procedure                 | : Caregiver Sat            | isfaction Que                          | stionnaire            |                            |  |
| ) Please rate your o          | overall satisfaction       | with your child's                      | IV start:             |                            |  |
| Very                          |                            |  |                       | Very                       |  |
| Dissatisfied<br>1             | Dissatisfied<br><b>2</b>   | Neutral<br>3                           | Satisfied<br><b>4</b> | Satisfied<br><b>5</b>      |  |
|                               | Ġ                          |  |                       |                            |  |
| Please Explain:               |                            |  |                       |                            |  |
|                               |                            |  |                       |                            |  |
|                               | 0                          |  |                       |                            |  |
| ) Please rate your s          | satisfaction with the      | e management of                        | your child's pain     | for their IV start:        |  |
| Very                          |                            |  |                       | Very                       |  |
| Dissatisfied                  | Dissatisfied               | Neutral                                | Satisfied             | Satisfied                  |  |
| <b>1</b><br>□                 | <b>2</b>                   | 3                                      | <b>4</b>              | 5<br>□                     |  |
| Please Explain:               |                            | 0                                      |                       |                            |  |
|                               |                            |  | 1                     |                            |  |
|                               |                            |  | 0                     |                            |  |
|                               |                            |  |                       |                            |  |
| ) Would you use th<br>future? | e same methods to          | manage your chi                        | ld's pain from nee    | edle pokes in the          |  |
|                               |                            |  |                       |                            |  |
| └ Yes<br>│ No                 |                            |  |                       |                            |  |
|                               |                            |  |                       |                            |  |
| Why / Why not?                |                            |  |                       |                            |  |
|                               |                            |  |                       |                            |  |
|                               |                            |  |                       |                            |  |
|                               |                            |  |                       |                            |  |
|                               | Thank you for you<br>it is | Ir participation in<br>very much appre |                       | ly,                        |  |
|                               |                            |  |                       |                            |  |
| VR Study CRE                  | ,                          | Version July 15 20                     | 20                    | Page 13 of 7               |  |



| REB #: Pro00095418   |  | Screening ID         |                      | Enrolment Date                                       |
|--|--|----------------------|----------------------|--|
| PI: Dr. Samina Ali   | VR   |                      |                      | // <u>2 0</u><br>ddmmyy                              |
| lurse Satisfactio  | on Questionnair  | e (VR Group)         |                      |  |
| 1) Overall, how easy   | or difficult was it to pe  | erform the IV inse   | tion for this child? |  |
| Very Easy<br>1   | Easy<br>2  | Neutral<br>3         | Difficult            | Very Difficult<br><b>5</b>                           |
| 2) Please rate your s  | atisfaction with this ch   | hild's IV start:     |                      |  |
| Very<br>Dissatisfied<br>1  | Dissatisfied   | Neutral<br>3         | Satisfied<br>4       | Very<br>Satisfied<br>5                               |
| <ul> <li>Would you use the from IV insertion in<br/>Yes</li> <li>No</li> </ul> | n the future?  | CZ.                  | •                    |  |
| <ol> <li>Could you please</li> </ol>   | rate the following on a  | a scale of 1-5, whe  | ere 1= Not at all ar |  |
|  | action with the Virtual<br>o use the VR device to<br>n the future  | ,                    | _                    | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| The degree to white<br>The degree to white                                     | ch the VR device implich the VR <b>improved</b> y<br>ch the VR <b>improved</b> y<br>ch the VR <b>disrupted</b> y | your ability to inse | rt the IV            |  |
| 5) Did the VR device<br>Yes (approx<br>No                                      | that was used during<br>imately how much tim   | •                    |                      | •  |
| <ol> <li>Is there anything e<br/>for a child using a</li> </ol>                | else that you would lik<br>VR device?  | e to tell us, today, | about your experi    | ence inserting an IV                                 |
|  |  |                      |                      |  |
|  |  |                      |                      |  |



| A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children:<br>The VR Study |   |                           |  |  |
|---|---|---------------------------|--|--|
| REB #: Pro00095418  | Screening ID  | Enrolment Date            |  |  |
| PI: Dr. Samina Ali  | VR  | // <u>2 0</u><br>dd mmm y |  |  |
| 7) How many years   | of practice do you have as a nurse (all settings)?    | N/A                       |  |  |
| 8) How many years   | of practice do you have as a nurse in the ED?         | _                         |  |  |
| 9) Please indicate th   | e amount of time spent in the pediatric emergency dep | partment (PED):           |  |  |
| 0.25% of r  | ny time is spent in the pediatric ED                  |                           |  |  |
|   |   |                           |  |  |
|   | my time is spent in the pediatric ED                  |                           |  |  |
|   | my time is spent in the pediatric ED                  |                           |  |  |
| ☐ 76-100% c   | of my time is spent in the pediatric ED               |                           |  |  |
|   |   |                           |  |  |
|   | Thank You!!   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   |   |                           |  |  |
|   | Version July 15, 2020                                 | Dago 1E of 1              |  |  |



|     |                                       |  | Screening ID             |                       | Enrolment              | Date            |
|-----|---------------------------------------|--|--------------------------|-----------------------|------------------------|-----------------|
| PI: | Dr. Samina Ali                        | VR   |                          | -                     | //<br>dd/              | <u>20</u><br>уу |
| Nu  | urse Satisfact                        | tion Questionnai   | re (Standard             | Care Group)           |                        |                 |
| 1)  | Overall, how easy                     | or difficult was it to pe  | erform the IV inser      | tion for this child?  | ,                      |                 |
|     | Very Easy<br>1                        | Easy<br>2  | Neutral<br>3             | Difficult 4           | Very Difficult<br>5    |                 |
| 2)  | Please rate your s                    | satisfaction with this ch  | nild's IV start:         |                       |                        |                 |
|     | Very<br>Dissatisfied<br>1             | Dissatisfied<br>2  | Neutral                  | Satisfied<br>4        | Very<br>Satisfied<br>5 |                 |
| -   | another child's pa                    | e same methods (ie. S<br>in and distress from IV                   | / insertion in the fu    | uture?                |                        |                 |
| 4)  | Could you please                      | rate the following on a  | a scale of 1-5, whe      | ere 1= Not at all ar  |                        | _               |
|     | Your overall satisf                   | action with the pain m   | anagement plan to        | 1<br>odav             |                        | 5<br>□          |
| •   | Your willingness to                   | o use a similar pain ma<br>pain and distress in th                 | anagement plan to        |                       |                        |                 |
|     | The degree to whi<br>experience       | ch the pain managem  | ent plan improved        | the child's           |                        |                 |
|     | The degree to whi<br>to insert the IV | ch the pain managem  | ent plan <b>improved</b> | <b>d</b> your ability |                        |                 |
|     | The degree to whi<br>to insert the IV | ch the pain managem  | ent plan <b>disrupte</b> | d your ability        |                        |                 |
|     | the time required                     | of Care pain managen<br>to insert the IV?<br>kimately how much tim | -                        |                       |                        | e               |
|     | Is there anything                     | else that you would lik<br>Standard of Care pair                   |                          | • •                   | ience inserting an     | IV              |



|                   |                      | The VR Study                               |                    |
|-------------------|----------------------|--|--------------------|
| REB #: Pro000954  | 118                  | Screening ID                               | Enrolment Dat      |
| PI: Dr. Samina Al |                      | VR   | // 2 (<br>dd/ 2 (  |
| 7) How many y     | ears of practice d   | o you have as a nurse (all settings)?      | N/A                |
| 8) How many y     | ears of practice d   | o you have as a nurse in the ED?           | N/A                |
| 9) Please indic   | ate the amount of    | time spent in the pediatric emergency de   | epartment (PED):   |
|                   | % of my time is so   | ent in the pediatric ED                    |                    |
|                   |                      | pent in the pediatric ED                   |                    |
|                   |                      | spent in the pediatric ED                  |                    |
|                   | •                    |  |                    |
| /0-1              | Ju 76 of my time is  | spent in the pediatric ED                  |                    |
|                   | ifu vour position if | other than attending ED nurse (e.g., IV I  | auroo attanding CD |
| , .               |                      | or nurse from other service [specify], etc |                    |
| priysician, re    | sident, physician    | of hurse from other service [specify], etc | )•                 |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      | Thank You!!                                |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
|                   |                      |  |                    |
| VR Study C        | DC                   | Version July 15, 2020                      | Page 17 of         |



| REB #: Pro00095418          | Screening      | ID     |           | Enrolment Da |
|-----------------------------|----------------|--------|-----------|--------------|
| PI: Dr. Samina Ali          | VR             |        |           | // 2         |
| )ischarge Informatio        | 'n             |        |           |              |
| Disposition                 |                | Disch  | narged Ho | ome          |
|                             |                |        |           |              |
|                             |                |        | <u> </u>  | /            |
| Date & Time of Discharge f  | rom the ED     | dd     | mmm<br>:  | уууу         |
|                             |                | (24 ho | ur clock) | -            |
| Length of Stay in ED (calcu | llated field): |        | urs       |              |
| Discharge Diagnosis         |                |        |           |              |
|                             |                |        |           |              |
|                             |                |        |           |              |
|                             |                |        |           |              |
|                             |                |        |           |              |



| REB #: Pro00095418                                      | Screening ID   | Enrolment Date              |
|---|--|-----------------------------|
| PI: Dr. Samina Ali                                      | VR   | // 2 0/ 2 0/ dd / yyy       |
| RA Satisfaction (                                       | Questionnaire (For Standard Care group, ans                                    | wer Q6 ONLY)                |
| ) Could you please ra                                   | te the following on a scale of 1-5, where 1= Not at all                        | and 5=Very much             |
| Marina and a state                                      |  | 1 2 3 4 5                   |
|   | action with the Virtual Reality (VR) device today                              |                             |
| Ease of set-up of the<br>Your satisfaction we<br>device | rith the amount of time it took to set up the VR                               |                             |
|   | k with the VR device again   |                             |
|   |  |                             |
|   | much time was needed to set up the VR device with t<br>and questionnaire time) | he child, today?            |
| minutes   |  |                             |
| Controller<br>Headphone<br>4) Were the VR Goggle        | es<br>es / Headset kept on for the entire duration of the proc                 | cedure?                     |
|   |  |                             |
|   |  |                             |
| 5) What applications /                                  | game(s) did the child play during the procedure?                               |                             |
| Check all that apply. I                                 | et / Smartphone  |                             |
| , .   | chnical or other issues with operating / handing the V                         | • •                         |
| <ol> <li>Is there anything els</li> </ol>               | e that you would like to tell us about your experience v                       | vith the VR googles today?  |
| VR Study CRF  | Version July 15, 2020  | Page <b>19</b> of <b>21</b> |



#### A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children:

| The | VR | Stu | dy |
|-----|----|-----|----|
|-----|----|-----|----|

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# **Adverse Events Log**

|     | To be filled out by Research Assistant |   |  |   |   |  | o be filled out          | by Site Investig  | ator               |                       |
|-----|--|---|--|---|---|--|--------------------------|---|--------------------|-----------------------|
| No. | Description of Adverse Event           | Onset<br>Date &<br>Time<br>(dd/mmm/<br>yyyy<br>HH:MM) | Action Taken<br>1.None<br>2.Medication<br>3.New or<br>Prolonged<br>Hospitalization<br>4.Procedure /<br>Surgery<br>5.Other, specify | Outcome<br>1.Resolved<br>2.Resolved with<br>Sequelae<br>3.Resolving<br>4.Unresolved<br>5.Fatal<br>6.Lost to follow-up | Date & Time<br>Resolved<br>(dd/mmm/<br>yyyy<br>HH:MM) | Intensity<br>grade:<br>1. Mild<br>2. Moderate<br>3. Severe | Expected<br>AE?<br>Y / N | Relationship<br>to Study<br>1.Unrelated<br>2.Unlikely<br>3.Possible<br>4.Probable<br>5.Definite | <b>SAE?</b><br>Y/N | Site<br>PI<br>Initial |
| 1   |  |   |  | 191   | ien   |  |                          |   |                    |                       |
| 2   |  |   |  |   |   | 0<br>7j  |                          |   |                    |                       |
| 3   |  |   |  |   |   |  |                          |   |                    |                       |



#### A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# **Early Withdrawal**

#### ONLY fill out this form in the event of an early withdrawal

| Date of Discontinuation:  | //<br>dd mmm yyyy   |
|---|---|
| Reasons for Discontinuation:<br>(check all that apply)  | <ul> <li>Adverse Event / Serious Adverse Event</li> <li>Death</li> <li>Withdrawal of Consent / Assent</li> <li>Protocol Violation, Specify</li> <li>Other, Specify</li> </ul> |
| If withdrew consent / assent:1. Permission to use collected data?2. Permission to conduct Chart Review? | ☐ Yes ☐ No<br>☐ Yes ☐ No  |
| Comments:   |   |
|   | 4   |
|   |   |

# Reporting checklist for protocol of a clinical trial.

| 7<br>8<br>9  |  |            | Reporting Item  | Page Number   |
|--|--|------------|---|---------------|
| 9<br>10<br>11<br>12<br>13<br>14  | Title  | <u>#1</u>  | Descriptive title identifying the study design,<br>population, interventions, and, if applicable, trial<br>acronym  | 1             |
| 15<br>16<br>17<br>18   | Trial registration   | <u>#2a</u> | Trial identifier and registry name. If not yet registered, name of intended registry  | 1             |
| 19<br>20   | Trial registration:  | <u>#2b</u> | All items from the World Health Organization  | 5-7 (Table 1) |
| 21<br>22   | data set   |            | Trial Registration Data Set   |               |
| 23<br>24   | Protocol version   | <u>#3</u>  | Date and version identifier   | 2             |
| 25<br>26<br>27<br>28   | Funding  | <u>#4</u>  | Sources and types of financial, material, and other support   | 14            |
| 28<br>29<br>30<br>31<br>32<br>33<br>34<br>35<br>36<br>37<br>38<br>39<br>40<br>41<br>42<br>43<br>44<br>45<br>46<br>47<br>48<br>49<br>50 | Roles and<br>responsibilities:<br>contributorship                | <u>#5a</u> | Names, affiliations, and roles of protocol contributors   | 15            |
|  | Roles and<br>responsibilities:<br>sponsor contact<br>information | <u>#5b</u> | Name and contact information for the trial sponsor  | 5             |
|  | Roles and<br>responsibilities:<br>sponsor and funder             | <u>#5c</u> | Role of study sponsor and funders, if any, in<br>study design; collection, management, analysis,<br>and interpretation of data; writing of the report;<br>and the decision to submit the report for<br>publication, including whether they will have<br>ultimate authority over any of these activities | 14            |
| 50<br>51<br>52<br>53<br>54<br>55<br>56<br>57<br>58   | Roles and<br>responsibilities:<br>committees                     | <u>#5d</u> | Composition, roles, and responsibilities of the<br>coordinating centre, steering committee,<br>endpoint adjudication committee, data<br>management team, and other individuals or   | N/A           |
| 59<br>60   |  | For peer   | review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml  |               |

|   |             | BMJ Open   | Page 48 of 5 |
|---|-------------|--|--------------|
|   |             | groups overseeing the trial, if applicable (see<br>Item 21a for data monitoring committee)   |              |
| Background and rationale                              | <u>#6a</u>  | Description of research question and justification<br>for undertaking the trial, including summary of<br>relevant studies (published and unpublished)<br>examining benefits and harms for each<br>intervention         | 4-5          |
| Background and<br>rationale: choice of<br>comparators | <u>#6b</u>  | Explanation for choice of comparators  | 7-8          |
| Objectives  | <u>#7</u>   | Specific objectives or hypotheses  | 5            |
| Trial design  | <u>#8</u>   | Description of trial design including type of trial<br>(eg, parallel group, crossover, factorial, single<br>group), allocation ratio, and framework (eg,<br>superiority, equivalence, non-inferiority,<br>exploratory) | 5            |
| Study setting   | <u>#9</u>   | Description of study settings (eg, community<br>clinic, academic hospital) and list of countries<br>where data will be collected. Reference to where<br>list of study sites can be obtained                            | 7            |
| Eligibility criteria                                  | <u>#10</u>  | Inclusion and exclusion criteria for participants.<br>If applicable, eligibility criteria for study centres<br>and individuals who will perform the<br>interventions (eg, surgeons, psychotherapists)                  | 7            |
| Interventions:<br>description                         | <u>#11a</u> | Interventions for each group with sufficient detail to allow replication, including how and when they will be administered   | 7-8          |
| Interventions:<br>modifications                       | <u>#11b</u> | Criteria for discontinuing or modifying allocated<br>interventions for a given trial participant (eg,<br>drug dose change in response to harms,<br>participant request, or improving / worsening<br>disease)           | 9,13         |
|   | For peer    | review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |              |

| Interventions:<br>adherance        | <u>#11c</u>   | Strategies to improve adherence to intervention<br>protocols, and any procedures for monitoring<br>adherence (eg, drug tablet return; laboratory<br>tests)  | 9   |
|------------------------------------|---|---|---|
| Interventions:<br>concomitant care | <u>#11d</u>   | Relevant concomitant care and interventions that<br>are permitted or prohibited during the trial  | 8   |
| Outcomes                           | <u>#12</u>  | Primary, secondary, and other outcomes,<br>including the specific measurement variable (eg,<br>systolic blood pressure), analysis metric (eg,<br>change from baseline, final value, time to event),<br>method of aggregation (eg, median, proportion),<br>and time point for each outcome. Explanation of<br>the clinical relevance of chosen efficacy and<br>harm outcomes is strongly recommended | 10-11   |
| Participant timeline               | <u>#13</u>  | Time schedule of enrolment, interventions<br>(including any run-ins and washouts),<br>assessments, and visits for participants. A<br>schematic diagram is highly recommended (see<br>Figure)  | 8-9 and Figure 3  |
| Sample size                        | <u>#14</u>  | Estimated number of participants needed to<br>achieve study objectives and how it was<br>determined, including clinical and statistical<br>assumptions supporting any sample size<br>calculations   | 11  |
| Recruitment                        | <u>#15</u>  | Strategies for achieving adequate participant<br>enrolment to reach target sample size  | 11  |
| Allocation: sequence<br>generation | <u>#16a</u><br>For peer   | Method of generating the allocation sequence<br>(eg, computer-generated random numbers), and<br>list of any factors for stratification. To reduce<br>predictability of a random sequence, details of<br>any planned restriction (eg, blocking) should be<br>provided in a separate document that is<br>unavailable to those who enrol participants or<br>assign interventions                       | 8   |
|                                    | adherance<br>Interventions:<br>concomitant care<br>Outcomes<br>Participant timeline<br>Sample size<br>Recruitment<br>Allocation: sequence | adherance #11d<br>Concomitant care #112<br>Outcomes #12<br>Participant timeline #13<br>Sample size #14<br>Recruitment #15<br>Allocation: sequence #16a  | adheranceprotocols, and any procedures for monitoring<br>adherence (eg, drug tablet return; laboratory<br>tests)Interventions:#11dRelevant concomitant care and interventions that<br>are permitted or prohibited during the trialOutcomes#12Primary, secondary, and other outcomes,<br>including the specific measurement variable (eg,<br>systolic blood pressure), analysis metric (eg,<br>ehange from baseline, final value, time to event),<br>method of aggregation (eg, median, proportion),<br>and time point for each outcome. Explanation of<br>the clinical relevance of chosen efficacy and<br>harm outcomes is strongly recommendedParticipant timeline#13Time schedule of enrolment, interventions<br>(including any run-ins and washouts),<br>assessments, and visits for participants. A<br>schematic diagram is highly recommended (see<br>Figure)Sample size#14Estimated number of participants needed to<br>achieve study objectives and how it was<br>determined, including clinical and statistical<br>assumptions supporting any sample size<br>calculationsAllocation: sequence<br>generation#16aMethod of generating the allocation sequence<br>(eg, computer-generated random numbers), and<br>list of any factors for stratification. To reduce<br>predictability of a random sequence, details of<br>any planned restriction (eg, blocking) should be<br>provided in a separate document that is<br>unavailable to those who enrol participants or |

#### Page 50 of 53

| 1<br>2<br>3<br>4<br>5<br>6<br>7<br>8   | Allocation<br>concealment<br>mechanism         | <u>#16b</u> | Mechanism of implementing the allocation<br>sequence (eg, central telephone; sequentially<br>numbered, opaque, sealed envelopes), describing<br>any steps to conceal the sequence until<br>interventions are assigned  | 8   |
|--|--|-------------|--|---|
| 9<br>10<br>11<br>12<br>13  | Allocation:<br>implementation                  | <u>#16c</u> | Who will generate the allocation sequence, who<br>will enrol participants, and who will assign<br>participants to interventions  | 8   |
| 14<br>15<br>16<br>17<br>18<br>19<br>20   | Blinding (masking)                             | <u>#17a</u> | Who will be blinded after assignment to<br>interventions (eg, trial participants, care<br>providers, outcome assessors, data analysts), and<br>how   | 8   |
| 21<br>22<br>23<br>24<br>25<br>26<br>27   | Blinding (masking):<br>emergency<br>unblinding | <u>#17b</u> | If blinded, circumstances under which<br>unblinding is permissible, and procedure for<br>revealing a participant's allocated intervention<br>during the trial  | N/A   |
| 27<br>28<br>29<br>30<br>31<br>32<br>33<br>34<br>35<br>36<br>37<br>38<br>39<br>40<br>41                   | Data collection plan                           | <u>#18a</u> | Plans for assessment and collection of outcome,<br>baseline, and other trial data, including any<br>related processes to promote data quality (eg,<br>duplicate measurements, training of assessors)<br>and a description of study instruments (eg,<br>questionnaires, laboratory tests) along with their<br>reliability and validity, if known. Reference to<br>where data collection forms can be found, if not<br>in the protocol | 8-9<br>and Appendix 2 for Case<br>Report Form |
| 42<br>43<br>44<br>45<br>46<br>47<br>48<br>49<br>50<br>51<br>52<br>53<br>54<br>55<br>56<br>57<br>58<br>59 | Data collection plan:<br>retention             | <u>#18b</u> | Plans to promote participant retention and<br>complete follow-up, including list of any<br>outcome data to be collected for participants<br>who discontinue or deviate from intervention<br>protocols  | 9   |
| 60   |  | For peer    | review only - http://bmjopen.bmj.com/site/about/guidelines.>   | ntml  |

#### Page 51 of 53

| 1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11  | Data management  | <u>#19</u>  | Plans for data entry, coding, security, and<br>storage, including any related processes to<br>promote data quality (eg, double data entry;<br>range checks for data values). Reference to<br>where details of data management procedures<br>can be found, if not in the protocol   | 12  |
|--|--|-------------|--|-----|
| 12<br>13<br>14<br>15<br>16<br>17<br>18   | Statistics: outcomes                                   | <u>#20a</u> | Statistical methods for analysing primary and<br>secondary outcomes. Reference to where other<br>details of the statistical analysis plan can be<br>found, if not in the protocol  | 11  |
| 19<br>20<br>21<br>22   | Statistics: additional analyses                        | <u>#20b</u> | Methods for any additional analyses (eg, subgroup and adjusted analyses)   | 11  |
| 23<br>24<br>25<br>26<br>27<br>28<br>29   | Statistics: analysis<br>population and<br>missing data | <u>#20c</u> | Definition of analysis population relating to<br>protocol non-adherence (eg, as randomised<br>analysis), and any statistical methods to handle<br>missing data (eg, multiple imputation)   | 11  |
| 30<br>31<br>32<br>33<br>34<br>35<br>36<br>37<br>38<br>39<br>40<br>41<br>42<br>43<br>44<br>45<br>46<br>47<br>48<br>49 | Data monitoring:<br>formal committee                   | <u>#21a</u> | Composition of data monitoring committee<br>(DMC); summary of its role and reporting<br>structure; statement of whether it is independent<br>from the sponsor and competing interests; and<br>reference to where further details about its<br>charter can be found, if not in the protocol.<br>Alternatively, an explanation of why a DMC is<br>not needed | N/A |
|  | Data monitoring:<br>interim analysis                   | <u>#21b</u> | Description of any interim analyses and stopping<br>guidelines, including who will have access to<br>these interim results and make the final decision<br>to terminate the trial   | N/A |
| 50<br>51<br>52<br>53<br>54<br>55<br>56<br>57<br>58<br>59   | Harms  | <u>#22</u>  | Plans for collecting, assessing, reporting, and<br>managing solicited and spontaneously reported<br>adverse events and other unintended effects of<br>trial interventions or trial conduct   | 11  |
| 60   |  | For peer    | review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |     |

| BMJ Open  |
|---|
| Frequency and procedures for auditing trial<br>conduct, if any, and whether the process will be<br>independent from investigators and the sponsor |
| Plans for seeking research ethics committee / institutional review board (REC / IRB) approval   |
|   |

- Protocol
   #25
   Plans for communicating important protocol

   amendments
   modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)
- Consent or assent#26aWho will obtain informed consent or assent from<br/>potential trial participants or authorised<br/>surrogates, and how (see Item 32)Consent or assent:#26bAdditional consent provisions for collection and

use of participant data and biological specimens

- Confidentiality#27How personal information about potential and<br/>enrolled participants will be collected, shared,<br/>and maintained in order to protect confidentiality<br/>before, during, and after the trial12Declaration of<br/>interests#28Financial and other competing interests for<br/>principal investigators for the overall trial and<br/>each study site13
  - Data access
     #29
     Statement of who will have access to the final
     Table 1

     trial dataset, and disclosure of contractual agreements that limit such access for investigators
     Table 1
- Ancillary and post#30Provisions, if any, for ancillary and post-trialN/Atrial carecare, and for compensation to those who suffer<br/>harm from trial participationN/ADissemination#31aPlans for investigators and sponsor to13
- 54Dissemination#31aPlans for investigators and sponsor to55policy: trial resultscommunicate trial results to participants,<br/>healthcare professionals, the public, and other58relevant groups (eg, via publication, reporting in<br/>For peer review only http://bmjopen.bmj.com/site/about/guidelines.xhtml

N/A

14-15

12-13

N/A

Auditing

approval

**Research ethics** 

ancillary studies

60

|   | results databases, or other data sharing<br>arrangements), including any publication<br>restrictions   |            |
|---|--|------------|
| 3Dissemination policy: authorship                 | #31b Authorship eligibility guidelines and any intended use of professional writers  | 15-16      |
| Dissemination<br>policy: reproducible<br>research | #31c Plans, if any, for granting public access to the<br>full protocol, participant-level dataset, and<br>statistical code   | Table 1    |
| Informed consent<br>materials                     | #32 Model consent form and other related<br>documentation given to participants and<br>authorised surrogates   | Appendix 1 |
| Biological specimens                              | <ul> <li>#33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable</li> </ul> | N/A        |
| <u>Network</u> in collaboration                   |  |            |
|   |  |            |

**BMJ** Open

# **BMJ Open**

#### A study protocol for a randomized controlled trial of virtual reality-based distraction for intravenous insertion-related distress in children

| Journal:                             | BMJ Open   |
|--------------------------------------|--|
| Manuscript ID                        | bmjopen-2021-057892.R1   |
| Article Type:                        | Protocol   |
| Date Submitted by the<br>Author:     | 12-Feb-2022  |
| Complete List of Authors:            | Ali, Samina; University of Alberta, Pediatrics<br>Rajagopal, Manasi; University of Alberta, Pediatrics<br>Stinson, Jennifer; Toronto SickKids<br>Ma, Keon; University of Calgary Cumming School of Medicine, Pediatrics<br>Vandermeer, Ben; University of Alberta, Pediatrics<br>Felkar, Bailey; London Health Sciences Centre, Pediatrics<br>Schreiner, Kurt; University of Alberta, Pediatric Parents' Advisory Group<br>Proctor, Amanda; Alberta Health Services<br>Plume, Jennifer; Alberta Health Services<br>Hartling, Lisa; University of Alberta, Pediatrics |
| <b>Primary Subject<br/>Heading</b> : | Paediatrics  |
| Secondary Subject Heading:           | Anaesthesia  |
| Keywords:                            | ACCIDENT & EMERGENCY MEDICINE, Pain management <<br>ANAESTHETICS, Paediatric A&E and ambulatory care < PAEDIATRICS,<br>PAIN MANAGEMENT   |
|                                      |  |

SCHOLARONE<sup>™</sup> Manuscripts

Title: A study protocol for a randomized controlled trial of virtual reality-based distraction for intravenous insertion-related distress in children Lay Title: Virtual Reality Based Distraction for Painful Procedures in Children Authorship: Samina Ali MDCM<sup>1,2,\*</sup>, Manasi Rajagopal MBT<sup>1</sup>, Jennifer Stinson<sup>3</sup>, Keon Ma MD<sup>4</sup>, Ben Vandermeer MSc<sup>5</sup>, Bailey Felkar MS CCLS<sup>6</sup>, Kurt Schreiner MPM<sup>7</sup>, Amanda Proctor<sup>8</sup>, Jennifer Plume BM, MA MTA<sup>9</sup>, Lisa Hartling PhD<sup>1,5</sup> 1 Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada 2 Women & Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada 3 Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children and the Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada 4 Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada 5 Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada 6 London Health Sciences Centre Children's Hospital, London, Ontario, Canada 7 Pediatric Parents' Advisory Group, University of Alberta, Edmonton, Canada 8 Stollery Youth Advisory Council and Patient and Family Centred Care, Edmonton, Alberta, Canada 9 Stollery Children's Hospital, Edmonton, Alberta, Canada \*denotes corresponding author, and contact for public and scientific inquiries 3-583 Edmonton Clinic Health Academy 11405 - 87 Avenue Edmonton, AB T6G 1C9 Phone: (780) 248-5574 Fax: (888) 775-8876 Email: sali@ualberta.ca Keywords: virtual reality, distress, pain, distraction, pediatrics, intravenous Trial Protocol Version 15 July 2020 Trial Registration: clinicaltrials.gov NCT04291404 WHO Trial Registration Data Set: See Table 1 Word Count: 3963/4000 words For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

The Virtual Reality Study Protocol Version 1.0

Ali S, Rajagopal M, et al

#### ABSTRACT

**Introduction.** Intravenous (IV) insertions are among the most performed procedures for children seeking medical care; they are often a painful and stressful experience for both children and their caregivers. Pediatric distress and pain that is inadequately treated may lead to a frightened and uncooperative child, repeated IV attempts and overall frustration with care for both the family and clinical team. We hypothesize that distraction via an immersive virtual reality (VR) experience may reduce the associated distress for children undergoing IV insertions.

#### Methods and analysis.

This two-armed randomized controlled superiority trial will be conducted in a Canadian pediatric emergency department and will aim to enroll 80 children overall. Children will be randomized to receive either departmental standard of care alone or standard of care plus an immersive VR experience. Children 6 to 17 years of age who are undergoing IV insertion and have topical anesthetic application will be considered for inclusion. Our primary objective is to compare the reduction of distress between the two study arms. The primary outcome will be the child's observed distress score as measured by the Observational Signs of Behavioral Distress-Revised (OSBD-R) tool. Secondary outcomes include the child's pain intensity and fear, parental anxiety, satisfaction with the IV procedure, as well as adverse events. Recruitment launched in September 2020 and is expected to end in March 2022.

**Ethics and dissemination.** This study has been approved by the Health Research Ethics Board (University of Alberta). Informed consent will be obtained from parents or guardians, and assent from children. Study data will be submitted for publication irrespective of results. This study is funded through a Women and Children's Health Research Institute Innovation grant. Purchase of the VR equipment was facilitated through a Stollery Children's Hospital Foundation small equipment grant.

Trial registration number: NCT04291404, First registered March 02, 2020

Words: 299/ 300

## Article Summary Strengths and limitations of this study

- 1. This randomized controlled trial will assess the effectiveness of immersive virtual reality-based distraction for the reduction of IV insertion-related distress in children.
- 2. This study measures patient- and family-relevant outcomes including child distress, pain, fear, and safety as well as parental anxiety and satisfaction.
- 3. The study team includes parent and patient partners as co-investigators who will inform study methods and outcomes.
- 4. The study intervention will be compared to current standard of care; however, since there is no consistent standard of care distraction practice, this may create some heterogeneity in the comparison arm of the study.
- 5. Given the nature of the study intervention, it is not possible to blind patients, parents/caregivers, health care providers, or outcome assessors; the statistician will be blinded to study arms.

The Virtual Reality Study Protocol Version 1.0

#### INTRODUCTION

Needle procedures, including venipuncture and intravenous (IV) placement, are described by children as some of the most distressing and painful parts of their healthcare visit. [1-4] Untreated distress and pain can lead to a scared and uncooperative child, a need for repeated IV attempts, reduced efficiency and overall dissatisfaction with care for the patient, family and the health care team. [3, 5, 6] Unpleasant medical encounters in childhood can also shape an individual's perception of healthcare and expectations of pain in adulthood. [7-9] This can result in increased anticipatory anxiety and pain for future medical procedures or an avoidance of healthcare services, altogether. [1] As needle procedures form a routine and necessary part of care in the emergency department (ED), it is an important responsibility of health care providers to adequately manage children's distress and pain, wherever possible.[10,11]

The recommended and responsible approach to managing children's procedural pain incorporates physical, psychological, and pharmacological components. [10-15] While pharmacological interventions such as topical anesthetic creams are available, their effectiveness is limited to *pain*, as they do not address procedure-related *distress and* anxiety. [10] Distraction therapy is a commonly employed psychological strategy which involves engaging children in a cognitive task or activity to divert attention away from nociceptive stimuli. [16] An effective distractor provides sensory stimulation and is highly engaging and age-appropriate to fully capture the attention of a child. [12,16] Previous research has indicated that children who use distraction as an active form of coping experience reduced pain and distress during painful procedures. [12, 17, 18] Traditional distraction techniques such as music, video, stories, imagery, and focused breathing have been previously explored for children undergoing unpleasant medical procedures and demonstrated mixed results. [19-24] Our team's recently conducted systematic review of digital technologies has suggested that digital distraction techniques appear promising, but require further study to confirm their utility for painful procedures. [25]

Virtual Reality (VR) technology is rapidly emerging as a novel distraction tool for children undergoing various medical procedures. Unlike traditional distraction techniques, VR uses a combination of visual, auditory, and tactile stimuli to create the illusion of being fully immersed in an artificial three-dimensional environment. [26] A Head Mounted Display (or 'VR goggles') delivers the VR video and audio to the child, and serves to block out the view and sounds of the hospital room. [14] This further removes the patient from the chaos of the treatment room and diverts their attention away from surrounding painful and anxiety-evoking stimuli. To date, VR distraction therapy has shown promise for patients undergoing a range of distressing healthcare procedures, including burn wound cleaning, chest radiography, dental interventions, and chemotherapy. [27-32] Therapeutic VR has also led to improved health outcomes for patients with anxiety disorders, phobias, post-traumatic stress disorder, and eating disorders. [33-36]

The Virtual Reality Study Protocol Version 1.0

The ED presents unique challenges when attempting to distract a child during a painful medical procedure. Due to the chaotic, noisy, and unpredictable environment, it is an ideal place to 'stress-test' the ability of VR technology to immerse a child into a distracting and 'safe' space. Rapid advances in VR technology over the last few years, and improved cost-effectiveness, offers a unique opportunity to explore its use in the ED setting. A few recently published studies from the pediatric ED setting suggest that VR has a positive impact on IV insertion-related pain and satisfaction, [12, 14, 37-40] although outcomes such as distress and adverse effects remain poorly studied. [38] Recent systematic reviews, which have mostly focused on non-ED and in-patient settings, have shown that the current evidence is inconclusive, sometimes contradictory, and have called for further research in larger study groups. [41-42] Furthermore many previous trials utilize proprietary software designed specifically for medical use which may limit widespread accessibility to all centers. This study will evaluate an "off-the-shelf" device with a range of widely accessible software.

This study will evaluate the effectiveness of a VR intervention in reducing IV placementrelated distress for children 6-17 years old presenting to the ED. We hypothesize that the use of immersive VR distraction will reduce children's IV related distress when compared with standard of care and will improve overall satisfaction with the procedure for the patient, family, and the health care team.

#### **METHODS AND ANALYSIS**

This study is a two-armed, randomized, controlled superiority trial. The study protocol is reported using the SPIRIT-PRO reporting guidelines. [43] (See Table 1.)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## Table 1. WHO Trial Registration Data Set

| Data Category                  | Information  |
|--------------------------------|--|
| Primary Registry and Trial     | clinicaltrials.gov NCT04291404                             |
| Identifying Number             |  |
| Date of Registration in        | March 2, 2020  |
| Primary Registry               |  |
| Secondary Identifying          | University of Alberta Research Ethics Board #              |
| Numbers                        | Pro00095418  |
| Source(s) of Monetary or       | Stollery Children's Hospital Foundation and the            |
| Material Support               | Women and Children Health Research Institute               |
|                                | Innovation Grant   |
| Primary Sponsor                | University of Alberta                                      |
| Secondary Sponsor(s)           | -  |
| Contact for Public Queries     | Dr. Samina Ali 780.248.5575 sali@ualberta.ca               |
| Contact for Scientific Queries | Dr. Samina Ali 780.248.5575 sali@ualberta.ca               |
| Public Title                   | The Virtual Reality Trial                                  |
| Scientific Title               | A randomized controlled trial of virtual reality-based     |
|                                | distraction for intravenous insertion-related distress in  |
|                                | children   |
| Countries of Recruitment       | Canada   |
| Health Condition(s) or         | Intravenous insertion-related distress                     |
| Problem(s) Studied             |  |
| Intervention(s)                | Addition of distraction via an immersive virtual reality   |
|                                | experience to departmental standard of care during the     |
|                                | intravenous (IV) insertion procedure                       |
| Key Inclusion and Exclusion    | To be eligible to participate in this study, an individual |
| Criteria                       | must meet all of the following inclusion criteria: (a)     |
|                                | child aged 6–17 years; (b) requires IV placement; and      |
|                                | (c) will receive topical anesthetic cream for IV           |
|                                | placement. Children meeting any of the following           |
|                                | criteria will be excluded: (a) medically unstable; (b)     |
|                                | unconscious or not fully alert; (c) visual, auditory       |
|                                | cognitive, or mental health issues precluding safe         |
|                                | interaction with the VR intervention; (d) conditions       |
|                                | that could be exacerbated by the VR environment,           |
|                                | such as <i>current</i> symptomatic nausea / vomiting /     |
|                                | dizziness/migraine, or a <i>history</i> of                 |
|                                | psychosis/hallucinations/epilepsy; (e) presence of an      |
|                                | infection/injury which could contaminate the VR            |
|                                | intervention equipment such as open wounds/                |
|                                | infections of the head and neck area, or                   |
|                                |  |

The Virtual Reality Study Protocol Version 1.0

| 1        |  |
|----------|--|
| 2        |  |
| 3        |  |
| 4        |  |
| 5        |  |
| 6        |  |
| 7        |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
| 12       |  |
|          |  |
|          |  |
| 14       |  |
| 15       |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 19       |  |
| 20       |  |
| 21       |  |
| 22       |  |
| 23       |  |
| 24       |  |
| 25       |  |
| 26       |  |
| 27       |  |
| 28       |  |
| 29       |  |
| 30       |  |
| 31       |  |
|          |  |
| 32       |  |
| 33       |  |
| 34       |  |
| 35       |  |
| 36       |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40       |  |
| 41       |  |
| 42       |  |
| 43       |  |
| 44       |  |
| 45       |  |
| 46       |  |
| 40<br>47 |  |
| 47       |  |
| 40<br>49 |  |
|          |  |
| 50       |  |
| 51       |  |
| 52       |  |
| 53       |  |
| 54       |  |
| 55       |  |
| 56       |  |
| 57       |  |
| 58       |  |
| 59       |  |
| 60       |  |

| positive for 'influenza-like illness' as per departmental<br>screening criteria; (g) language barrier precluding the<br>ability to understand and complete study assessments,<br>in the absence of a native language translator; or (h)<br>previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAL-S,<br>Form Y); (d) satisfaction with the procedure inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case |                        | <i>Staphylococcus aureus</i> colonization; (f) screens  |
|--|------------------------|---|
| screening criteria; (g) language barrier precluding the<br>ability to understand and complete study assessments,<br>in the absence of a native language translator; or (h)<br>previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case    |                        | 1.0   |
| ability to understand and complete study assessments,<br>in the absence of a native language translator; or (h)<br>previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-PD sharing statementDe-identified data can be shared, on a case-by-case  |                        |   |
| in the absence of a native language translator; or (h)<br>previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, a sasessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        |   |
| previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likett scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro0095418Completion date-PD sharing statementDe-identified data can be shared, on a case-by-case  |                        |   |
| Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion dateSummary ResultsIPD sharing statementDe-identified data can be shared, on a case-by-case  |                        |   |
| Date of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   | Study Type             | 1 ž   |
| Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-PD sharing statementDe-identified data can be shared, on a case-by-case   |                        | 1 ž   |
| Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        | · · · · · · · · · · · · · · · · · · ·                   |
| Primary Outcome(s)The primary outcome will be the child's total observed<br>distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  | <b>1</b>               |   |
| distress score during the IV procedure as measured on<br>the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  |                        |   |
| the Observational Signs of Behavioral Distress-<br>Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   | Primary Outcome(s)     | 1 5   |
| Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (c) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  |                        | e 1   |
| Key Secondary OutcomesSecondary outcomes include: (a) the child's self-<br>reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  |                        | e e   |
| reported pain score during the IV procedure, using an<br>11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        |   |
| 11-point 0-10 verbal Numerical Rating Scale (vNRS);<br>(b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  | Key Secondary Outcomes | 5   |
| (b) the child's self-reported fear score during the IV<br>insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        |   |
| insertion as measured by the Children's Fear Scale<br>(CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        |   |
| (CFS); (c) parental/caregiver anxiety associated with<br>the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        | (b) the child's self-reported fear score during the IV  |
| the procedure, as assessed by the State Trait Anxiety<br>Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  |                        | insertion as measured by the Children's Fear Scale      |
| Inventory - State Trait Revised Version (STAI-S,<br>Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        | (CFS); (c) parental/caregiver anxiety associated with   |
| Form Y); (d) satisfaction with the procedure for the<br>child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        | the procedure, as assessed by the State Trait Anxiety   |
| child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        | Inventory - State Trait Revised Version (STAI-S,        |
| child, their parent/caregiver and the nurse inserting the<br>IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        | Form Y); (d) satisfaction with the procedure for the    |
| IV, as assessed by a 5-point Likert scale; and (e) the<br>proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  |                        |   |
| proportion of children who experience adverse events<br>related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  |                        |   |
| related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  |                        |   |
| Ethics ReviewUniversity of Alberta Research Ethics Board #<br>Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case  |                        |   |
| Pro00095418         Completion date       -         Summary Results       -         IPD sharing statement       De-identified data can be shared, on a case-by-case  | Ethics Review          |   |
| Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case   |                        |   |
| IPD sharing statementDe-identified data can be shared, on a case-by-case   | Completion date        | -   |
|  | Summary Results        | -   |
|  |                        | De-identified data can be shared, on a case-by-case     |
|  |                        | basis, upon discussion with the principal investigator. |
|  |                        |   |

Ali S, Rajagopal M, et al

#### Setting and Study Period

This study will be conducted in the Stollery Children's Hospital (SCH) emergency department in Edmonton, Alberta, Canada. The SCH is a tertiary care hospital whose annual ED census is typically approximately 60,000. The 2020 ED census for the SCH was reduced to 36,899 due to the COVID-19 pandemic. Recruitment launched in September 2020 and is expected to end in March 2022. Based on our team's previous experience conducting research in this setting, and considering the ongoing pandemic-related considerations, we anticipate 18 months of recruitment to meet our overall target of 80 patients.

#### **Eligibility and Exclusion Criteria**

Children will be eligible if they are 6 to 17 years, require an IV placement during their ED visit, and have received topical anesthetic cream for their IV placement. This age group was chosen as they can reliably self-report pain and are expected to benefit from the virtual reality study intervention, based on prior studies. [44] Due to ethical and pragmatic considerations, we insisted that children must be receiving topical anesthetic cream for IV placement to be eligible for our study, as it is effective and considered standard of care within our hospital. [10] Exclusion criteria are detailed in Table 1.

#### **Study Intervention and Comparison**

The intervention will include the use of an immersive VR application that will engage children for the duration of the IV procedure. The VR intervention will be provided in addition to standard of care. The child will wear the VR goggles (Oculus Quest, Oculus, Facebook Technologies, LLC; see Figure 1) and small handheld controllers (optional) can be used to interact with the virtual environment and change settings. The VR goggles will occlude the patient's view of the treatment room, and a pair of noise-cancelling headphones (optional) can be used to block out ambient hospital sounds. Together, this will provide the child with a unique vivid experience of being fully immersed or "present" inside the 3D virtual world. The child will be presented with one of two VR menu options, one for novice users and another for more experienced users. The menus will have pre-selected VR applications that are suitable for use during the IV procedure and will include a combination of interactive games and immersive 3D movies designed specifically for a virtual reality experience (see Figure 2). The choice of applications was based on consultation with the Stollery Children's Hospital Youth Advisory Committee prior to commencing the study. The shortlisted applications were then tested by the principal investigators, other team members, and youth. The research assistant (RA), who will be trained in proper equipment use and troubleshooting, will help the child with selecting and running the VR game/movie. Based on child and nursing preference, children may either sit up or lie in a supine position for the duration of the procedure. The chosen VR games will not require the child to move their torso or both arms, to not interfere with the IV placement. The VR goggles can be removed at any time during the procedure if the child so desires. The game/application selected by the child will be recorded on the case report form.

The Virtual Reality Study Protocol Version 1.0

The control group will receive departmental standard of care which will include topical anesthetic cream (mandatory for inclusion in the study) and may include parent/caregiver support, child life services, nursing support, and other support strategies at the discretion of the ED clinical care team and the family. Child life services include pre-procedural education, distraction and coaching, intra-procedural presence, and post-procedural support and prizes. At present, there is no single established distraction therapy or routine that is consistently employed for IV procedures within our ED. Thus, for pragmatic and ethical considerations, it is felt that the new study VR intervention should be compared to what is currently already in practice (i.e., standard of care). Generally, VR technology is not employed by the nursing staff for distracting the child. However, other forms of technology (i.e., smart phones, tablets) will *not* be prohibited in the control group if the family chooses to offer them. Use of other devices and distraction techniques will be documented.

# Randomization, Allocation Concealment, and Blinding

Randomization will be determined using an online randomization tool hosted on the REDCap [45] (Research Electronic Data Capture) platform. Following documentation of informed consent and assent, the RA will obtain the computer-generated randomized assignment for the child by clicking on the 'Randomize' button within the study-specific REDCap case report form. Allocation will be concealed from the research staff, ED clinical staff and the family until this point. However, due to the nature of the intervention, it is not possible to maintain blinding once the child has been randomized.

Children and their parents/caregivers will be informed that the study will evaluate and compare different forms of distraction, however they will not be made aware of the study hypothesis for the VR intervention. Furthermore, the statistician will be blinded to treatment assignment by using randomization codes until data analysis is complete.

# **Recruitment and Data Collection**

Participant recruitment will occur in the SCH ED when RAs are on-site, from approximately 15:00 to 23:00 daily. Based on our team's previous research, this time frame corresponds with peak ED volume. RAs will screen the electronic ED track board and communicate with on-site clinical staff to identify potentially eligible patients. The RA will then further assess eligibility based on the inclusion/exclusion criteria detailed above. If the child is deemed eligible and the family is willing to participate, the RA will obtain written informed consent from the parent/ caregiver and assent from the child (See Appendix 1). One parent/caregiver for each child will be asked to provide consent and complete all relevant study questionnaires.

Prior to the beginning of the IV procedure, the RA will collect baseline information, including: baseline heart rate, pre-procedure distress, fear, and pain scores from the child, and pre-procedure anxiety score from the parent/caregiver. The RA will then access the randomization tool on REDCap to reveal the child's group assignment (VR intervention or Control).

Ali S, Rajagopal M, et al

For the VR intervention group, the RA will set up the VR equipment and spend approximately 5-10 minutes explaining the intervention to the child, including proper use of the goggles and controller. The RA will then help the child put on and secure the goggles and headphones, and hand them the controller. They will document the time required for equipment set up as well as any technical challenges encountered. As per hospital infection control policy, all VR equipment including the goggles, headphones and controller will be sanitized with disinfectant wipes between participants. A disposable one-time use cover will be placed on the goggles for each participant. For all participants (both study arms), the RA will begin video recording the child five minutes prior to the start of the procedure and continue until 5 minutes post-procedure, to allow for complete coding of OSBD-R distress scores at a later time.

For all participants (both study arms), the staff nurse will insert the IV following institutional protocol. In keeping with the pragmatic design of the trial, no additional or study-specific instructions will be provided to either nurses or parents/caregivers regarding their behaviour during the procedure. For purposes of the study, the start of the IV insertion procedure will be marked by the cleaning of the IV site by the staff nurse. The end of the procedure will be defined by the last point of contact by the staff nurse (i.e., taping cannula in place with or without arm board, wrapping arm with gauze and taping the gauze in place).

During the procedure, the RA will closely monitor the child for any adverse effects. The child will also be asked to let the team know immediately if they are experiencing any adverse events or discomfort related to the VR intervention (i.e., dizziness, nausea, headache). The VR intervention can be discontinued (i.e., the headset can be removed) at any time, at the discretion of the child or clinical team. If an adverse event were to occur, the clinical team will be notified, and details will be logged in the REDCap adverse event log. Additionally, the RA will make a note of any technical failures or issues associated with the VR equipment during enrollment.

Immediately following the first *attempt* at IV placement (regardless of whether it was successful), the RA will collect post-procedure distress, fear and pain scores from the child, and post-procedure anxiety score from the parent/caregiver. A few minutes after completion of the IV placement, satisfaction and acceptability questionnaires will be completed with the child, parent /caregiver as well as the staff nurse responsible for

inserting the IV. Five minutes after the procedure is completed, the RA will stop the

video recording. The duration of the procedure and total number of IV attempts will be documented. If the first attempt at placement is unsuccessful, any additional attempts will occur after all relevant study questionnaires/measurements have been completed.

Demographic information, previous history and visit details will also be collected from the family and the child's medical chart. See Figure 3 for study flow schematic.

#### **Outcome Measures**

Our primary outcome is **distress**. Our secondary outcomes are (a) pain; (b) fear; (c) the parental/caregiver anxiety; and (d) parental/caregiver and nurse satisfaction with the procedure in the intervention; and (e) safety.

The Virtual Reality Study Protocol Version 1.0

Our primary outcome measure will be the child's total distress score during the IV procedure. Distress associated with the procedure will be assessed using the Observational Scale of Behavioral Distress-Revised (OSBD-R). The OSBD-R is a validated scale that is widely used to measure pain and distress associated with various medical procedures in children. [46-48] The tool assesses eight specific behaviors that are indicative of distress and are weighted according to intensity: information seeking, crying, screaming, restraint, verbal resistance, emotional support, verbal pain, and flailing. Study participants will be videotaped for the duration of the IV procedure as well as for a few minutes before and after; distress will be scored pre-, during, and postprocedure. Two RAs who are trained in the use of the tool will independently observe the videotapes and record the frequency of each of the eight behaviors during continuous 15second intervals. To ensure high inter-rater reliability, the first 10% of coded videos will be analyzed for inter-rater reliability and RAs will be provided with feedback and retraining, as needed, prior to coding the remaining videos. The mean OSBD-R scores between the two RAs will be used as the final scores. This standardized procedure for OSBD-R has been successfully used in previous research evaluating distraction. [29, 49-52] This scale demonstrates high inter-rater reliability as well as moderate to high correlations with other behavioral measures of distress. [49, 53-54]

Our principal secondary outcome measure will be the child's pain score during the IV procedure. Pain will be measured using an 11-point verbal Numerical Rating Scale (vNRS) ranging from 0 (no pain) to 10 (worst possible pain). This scale is a commonly used pain measurement tool in pediatric acute pain studies and is validated for use in children 6-17 years of age. [55-58] Pain scores will be self-reported by children both before and immediately following the IV procedure.

Fear will be measured using the Children's Fear Scale (CFS) [4, 59]. This scale depicts five faces representing increasing levels of anxiety, where the left-most face depicts "not scared at all" (score=0) and the right most-face means "most scared possible" (score=4). The CFS is an adaptation of the adult Faces Anxiety Scale [59] and has been validated to measure fear in children undergoing painful medical procedures. [4] Children will be asked to independently rate their fear both before and immediately following the IV procedure.

Parental/Caregiver anxiety will be measured with the State Trait Anxiety Inventory – State Scale Revised Version (STAI-S, Form Y), a validated and commonly used version of STAI, which has improved psychometric properties. [60] Parents/caregivers will be asked to complete the STAI questionnaire both before and immediately following the IV procedure. The Virtual Reality Study Protocol Version 1.0

Parent/caregiver and nurse satisfaction with the procedure will be measured using a 5-point Likert scale, ranging from 1 "Very dissatisfied" to 5 "Very satisfied". Child satisfaction with the procedure will be measured using a 5-point Likert scale, ranging from 1 "Not at all happy" to 5 "Very happy". Satisfaction scores will be collected immediately following the IV procedure.

Safety of the VR intervention will be determined by assessing the frequency of adverse events post intervention. Specifically, nausea will be self-rated by children immediately following the intervention, using the Baxter Retching Faces (BARF) scale [61]. This scale consists of 6 faces depicting increasing levels of nausea, with assigned scores ranging from 0 to 10. The BARF scale is widely used in medical research and has demonstrated construct, content, and convergent validity as a tool to measure nausea in children. [61] The presence of other adverse events (i.e., dizziness) will also be recorded by the RA. Children who are presenting with nausea, vomiting, dizziness or migraines *prior* to enrollment will be excluded from the study to avoid exacerbating these conditions with the use of the VR equipment.

# Sample Size

The sample size for the study is 80 patients overall. Sample size calculations were conducted using a two-tailed, two-sample Mann-Whitney test for the primary outcome of observed behavioral distress based on data from the team's previous trial of digital distraction. To detect a large effect size of 0.6 on the OSBD-R (which was observed in a previous trial), given a Type I error of 0.05 and 80% power, the study will require 35 patients for each of the two study arms. To account for attrition and technical recording failures, the team will plan to over-recruit by 10-15%, for an overall total of 80 patients. This will allow sufficient power to find a difference in the primary outcome if a difference truly exists.

# **Statistical Methods**

Statistical analyses will be conducted using statistical software SAS (version 9: SAS Institute, Cary, NC). The significance level will be set at 0.05. Baseline variables will be described using appropriate summary statistics for each group. Imbalances between groups for key baseline variables will indicate the need for further adjusted analyses. For the primary outcome of observed behavioral distress, total OSBD-R scores will be compared between the two groups using independent samples t-tests if they are normally distributed or Mann-Whitney U-tests if they are skewed (the Sidak correction procedure will be used to reduce the probability of a Type I error). Additional model-based analyses (multiple linear regression) will be conducted, as needed, with behavioural distress as the response variable, pre-procedure behavioral distress and group indicators as the explanatory variables along with some possible effect modifiers such as age, sex, and parental/caregiver anxiety levels. Our primary analysis will be based on an intention-totreat approach where all children who were randomly assigned to a study group will be included in the group to which they were randomized. Where cell sizes are small or data are sparse or missing, proxy information or appropriate imputation methods will be used as needed. Similar approaches will be used to compare the groups with respect to secondary outcomes if appropriate.

# Patient and Public Involvement

The team's parent advisor (KS) has provided ongoing input on the study protocol and design, and has provided valuable feedback on the content, flow and readability of the consent forms and data collection forms. The Stollery Youth Advisory Council, led by team member AP, provided input on the study design, outcomes measures, and types of virtual reality applications that might be engaging and practical for our study population. AP also reviewed the study protocol and related documents to ensure that the outcomes and tools were patient-relevant and age-appropriate. Following recruitment completion, parent and youth advisors will be further engaged to discuss study results and dissemination plans in the context of patient- and family-centered care.

# Data Management and Confidentiality

Data will be entered into a secure online REDCap [45] database hosted by the Women and Children's Health Research Institute (WCHRI). (See Appendix 2 for Case Report Form.) WCHRI's REDCap installation is a validated electronic, web-based data capture system housed in a secure data center at the University of Alberta. Data is entered into REDCap through a web-based interface using 128-bit SSL encryption. Each team member will be granted an individual username/ password and will require additional two factor authentication to log in. All datasets used for statistical analysis will be encrypted and devoid of any patient identifiers. For internal data quality control, a secure master list will be maintained to accurately link study IDs to the patient's medical record.

Selected data elements will be validated electronically throughout the recruitment period and any discrepancies will be assigned to team members for timely resolution. REDCap includes internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.

Study data will be entered directly into REDCap in real-time via research iPads or, in some cases (i.e., parent/caregiver indicate a preference to complete paper-based questionnaires), responses may be collected on paper first and then transcribed into REDCap by a trained RA. All paper documents (including study questionnaires, consent/assent forms, and the master list) will be stored in a locked cabinet in a secure location that is only accessible to authorized research staff members. Study videos will be stored electronically in a secure institutional shared drive with restricted access to study staff. Videos will be stored on a secure server and computers at the University of Alberta. Following completion of the study, all data will continue to be kept in a secure location for five years as dictated by the research ethics board.

# ETHICS AND DISSEMINATION

This study has received approval from the Health Research Ethics Board (HREB) at the University of Alberta (HREB identifier: Pro00073476). Any amendments to the study protocol or documents will be submitted for HREB review and will receive approval prior to implementation. Significant protocol amendments will also be reflected online on

Ali S, Rajagopal M, et al

the clinicaltrials.gov study registration. This study has also received operational approval from the SCH ED.

All children will receive the best possible care for their presenting complaint, regardless of whether they choose to participate. It is possible that patients in the VR intervention group may experience nausea, mild motion sickness or dizziness, however these effects are rare in children and adolescents, ranging from 0-5%. [62, 63] VR applications have been selected appropriately to minimize these discomforts, and children are monitored closely throughout the study for any adverse effects. Children experiencing nausea, vomiting, dizziness or migraine headaches prior to enrollment will be excluded to avoid potential exacerbation. Study participation is unlikely to prolong the ED length of stay. For infection-control purposes, children screening positive for 'influenza-like illness' (as per ED screening criteria) are excluded to prevent potential contamination of the VR equipment.

Due to resource/logistical constraints, study recruitment will be limited to Englishspeaking families or those with their own interpreter, at a single recruiting center, and during RA shift hours only. Critically ill children requiring immediate IV insertion will also be excluded to avoid delaying medical care. This may limit the generalizability of the study findings. We will not be controlling for the type of distraction used in the standard of care arm, but we will record what was employed. While this may create some heterogeneity in the comparison arm of the study, it will be a pragmatic reflection of clinical reality. Due to the nature of the intervention, blinding is not possible for the participants or the research personnel, though the statistician will be blind to study group.

The study team plans to publish trial results in a high-impact, peer-reviewed journal and present results at national and international meetings; authorship eligibility will be determined by employing the International Committee of Medical Journal Editors' recommended guidelines. [64] Statistical code and dataset can be made available upon request.

**Competing Interests** None declared.

**Patient Consent** After assessing eligibility based on the outlined inclusion/exclusion criteria, research assistants will obtain consent from the parents/caregivers (and assent from children older than 6 years) prior to enrolling the child in the study. The research assistant will provide both a verbal and written explanation of the study to the family. The family will be given an opportunity to review the consent/assent forms in private and can ask the research assistant any questions they might have prior to signing the consent/assent forms. The family is free to withdraw at any point during the study.

<u>Acknowledgments</u> The authors would like to thank the members of the Stollery Youth Advisory Council, who provided valuable input on the study design and gaming/application choices for the virtual reality headsets.

#### The Virtual Reality Study Protocol Version 1.0

#### **FUNDING STATEMENT**

This work is funded by the generosity of the Stollery Children's Hospital Foundation through the Women and Children's Health Research Institute Innovation Grant. Purchase of the virtual reality goggles was facilitated through a generous small equipment grant from the Stollery Children's Hospital Foundation. The funders do not have any role in the collection, management, analysis, or interpretation of data; writing of the report; or the decision to submit the report for publication. Dr. Hartling is supported by a Canada Research Chair in Knowledge Synthesis and Translation and is a Distinguished Researchers with the Stollery Science Lab supported by the Stollery Children's Hospital or oper terien only Foundation.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# AUTHOR CONTRIBUTIONS

Dr. Samina Ali (SA) is a pediatric emergency clinician-researcher and Professor of Pediatrics & Emergency Medicine at the University of Alberta. She co-developed and revised the protocol and co-drafted the protocol paper. She chose the previously validated tools for measuring the primary outcomes.

Manasi Rajagopal (MR) is the program lead for the Pediatric Emergency Medicine research program at the University of Alberta and co-principal investigator of this study. She co-developed the study protocol, co-drafted the protocol paper, and will operationalize the study.

Dr. Jennifer Stinson (JS) is the Mary Jo Haddad Nursing Chair in Child Health at the Hospital for Sick Children's Research Institute and a nurse practitioner in the Department of Anesthesia's chronic pain program at the hospital. She assisted with the study design and protocol revision.

Dr. Keon Ma is a pediatric trainee at the University of Calgary, with expertise in OSBD-R coding. He assisted with the study design and protocol revision.

Ben Vandermeer (BV) led the statistical analysis planning and contributed to protocol revision.

Bailey Felkar (BF) is a child life specialist at the Stollery ED with expertise in managing children's pain and distress in the ED setting. She assisted with the study design and protocol revision.

Kurt Schreiner (KS) is a family partner who has provided input into study outcomes to ensure family-relevant outcomes are chosen and will inform our knowledge translation efforts to the public.

Amanda Proctor (AP) is the coordinator of the Stollery Youth Advisory Council. Together with the council, she informed programming choices for the virtual reality devices and has reviewed the protocol and related documents to ensure that the outcomes and tools are patient-relevant and age-appropriate.

Jennifer Plume (JP) is the acting director for Stollery child life services with expertise in managing children's pain and distress in the ED. She has informed study methods and will aid and support the development of our knowledge translation plan.

Dr. Lisa Hartling (LH) is a Professor in the Department of Pediatrics at the University of Alberta and Director of the Alberta Research Centre for Health Evidence (Edmonton, Canada). She assisted with the study design and drafting the protocol, and provides expertise in clinical trial methodology and statistical analyses.

The Virtual Reality Study Protocol Version 1.0

All authors have approved this final version of the protocol. None of the authors have financial or other conflicts of interests as they pertain to this study and its involved recruitment sites.

tor occr terien ont

### **Figures Legend**

Figure 1. Child using virtual reality goggles in the emergency department Figure 2. Virtual Reality Game Menus Figure 3. Flow Diagram of Study Procedures

tor peer teriew only

tor peer terien ont

The Virtual Reality Study Protocol Version 1.0

#### REFERENCES

- 1. Stevens BJ, Abbott LK, Yamada J, et al; CIHR Team in Children's Pain. Epidemiology and management of painful procedures in children in Canadian hospitals, *Canadian Medical Association Journal*. 2011 Apr 19;183(7):E403-10.
- 2. Duff AJA. Incorporating psychological approaches into routine paediatric venepuncture, *Archives of Disease in Childhood* 2003;88:931-7 doi:10.1136/adc.88.10.931.
- 3. Sanchez Cristal N, Staab J, Chatham R, et al. Child Life Reduces Distress and Pain and Improves Family Satisfaction in the Pediatric Emergency Department, *Clin Pediatr (Phila)* 2018;57:1567-75 doi:10.1177/0009922818798386.
- 4. McMurtry CM, Noel M, Chambers CT, et al. Children's fear during procedural pain: Preliminary investigation of the Children's Fear Scale, *Health Psychology* 2011;30:780-8 doi:10.1037/a0024817.
- 5. McGrath PJ, McAlpine L. Psychologic perspectives on pediatric pain, *The Journal of Pediatrics* 1993;122:S2-8 doi:10.1016/S0022-3476(11)80002-8.
- 6. Drendel AL, Ali S. Ten Practical Ways to Make Your ED Practice Less Painful and More Child-Friendly, *Clinical Pediatric Emergency Medicine*. Volume 18, Issue 4, December 2017, 242- 255.
- 7. El-Housseiny AA, Alamoudi NM, Farsi NM, et al. Characteristics of dental fear among Arabic-speaking children: a descriptive study, *BMC Oral Health* 2014;14 doi:10.1186/1472-6831-14-118.
- 8. Fields H. How expectations influence pain, *Pain* 2018;159:S3-S10 doi:10.1097/j.pain.00000000001272.
- 9. Noel M, Rabbitts JA, Tai GG, et al. Remembering Pain after Surgery: A Longitudinal Examination of the Role of Pain Catastrophizing in Children's and Parents' Recall, *Pain* 2015;156:800 doi:10.1097/j.pain.000000000000102.
- 10. Trottier ED, Doré-Bergeron MJ, Chauvin-Kimoff L, et al. Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures. [CPS Position Statement], *Paediatrics & Child Health* 2019;24:509-21.
- 11. Friedrichsdorf SJ, Eull D, Weidner CA. A Children's Comfort Promise: how can we do everything possible to prevent and treat pain in children using quality improvement strategies? *Pediatric Pain Letter* 2016;18:26-30.
- 12. Dumoulin S, Bouchard S, Ellis J, et al. A Randomized Controlled Trial on the Use of Virtual Reality for Needle-Related Procedures in Children and Adolescents in the Emergency Department. , *Games for Health Journal* 2019;8:285-93.
- 13. Jain S, Hegenbarth MA, Humiston SG, et al. Increasing ED use of jet injection of lidocaine for IV-related pain management , *Pediatrics* 2017;139:e20161697.
- 14. Chan E, Hovenden M, Ramage E, et al. Virtual Reality for Pediatric Needle Procedural Pain: Two Randomized Clinical Trials, *The Journal of Pediatrics* 2019;209:160,167.e4 doi:10.1016/j.jpeds.2019.02.034.
- 15. Gaskell S. Evidence-based guidelines for the management of invasive and/or distressing procedures with children, *British Journal of Social Psychology* 2019.
- 16. McCaul KD, Malott JM. Distraction and coping with pain, Pain 1985;23:315.
- 17. Manne SL, Bakeman R, Jacobsen PB, et al. An analysis of a behavioral intervention for children undergoing venipuncture, *Health Psychology* 1994;13:556-66.

4

5

6

7

8 9

10

11

12

13

14

15

16 17

18

19

20

21

22

23

24 25

26

27

28

29

30

31 32

33

34

35

36

37

38

39 40

41

42

43

44

45

46 47

48

49

50

51

52

53

54

60

18. Vessey JA, Carlson KL, McGill J. Use of distraction with children during an acute pain experience, Nursing Research 1994;43:369-72 doi:10.1097/00006199-199411000-00009. 19. Klassen JA, Liang Y, Tjosvold L, et al. Music for Pain and Anxiety in Children Undergoing Medical Procedures: A Systematic Review of Randomized Controlled Trials, Ambulatory Pediatrics 2008;8:117-28 doi:10.1016/j.ambp.2007.12.005. 20. Cohen LL, Blount RL, Panopoulos G. Nurse Coaching and Cartoon Distraction: An Efective and Practical Intervention to Reduce Child, Parent, and Nurse Distress During Immunizations, J Pediatr Psychol 1997;22:355-70 doi:10.1093/jpepsy/22.3.355. 21. Cassidy K, Reid GJ, McGrath PJ, et al. Watch Needle, Watch TV: Audiovisual Distraction in Preschool Immunization, Pain Med 2002;3:108-18 doi:10.1046/j.1526-4637.2002.02027.x. 22. Downey LVA, Zun LS. The Impact of Watching Cartoons for Distraction During Painful Procedures in the Emergency Department, Pediatric Emergency Care 2012;28:1033 doi:10.1097/PEC.0b013e31826cac1a. 23. Young T, Griffin E, Phillips E, et al. Music as Distraction in a Pediatric Emergency Department, Journal of Emergency Nursing 2010;36:472-3 doi:10.1016/j.jen.2010.05.014. 24. Ha YO, Kim HS. The effects of audiovisual distraction on children's pain during laceration repair, International Journal of Nursing Practice 2013;19:20-7 doi:10.1111/ijn.12165. 25. Gates M, Hartling L, Shulhan-Kilroy J, et al. Digital Technology Distraction for Acute Pain in Children: A Meta-analysis, Pediatrics 2020;145 doi:10.1542/peds.2019-1139. 26. Ahmadpour N, Randall H, Choksi H, et al. Virtual Reality interventions for acute and chronic pain management, International Journal of Biochemistry & Cell Biology 2019;114:105568. 27. Sikka N, Shu L, Ritchie B, et al. Virtual Reality-Assisted Pain, Anxiety, and Anger Management in the Emergency Department, *Telemedicine and e-Health* 2019. 28. Hoffman HG, Doctor JN, Patterson DR, et al. Use of virtual reality for adjunctive treatment of adolescent burn pain during wound care: A case report, Pain 2000;1-2:305-9. 29. Han S, Park J, Choi SI, et al. Effect of Immersive Virtual Reality Education Before Chest Radiography on Anxiety and Distress Among Pediatric Patients: A Randomized Clinical Trial, JAMA pediatrics 2019 doi:10.1001/jamapediatrics.2019.3000. 30. Shetty V, Suresh LR, Hegde AM. Effect of Virtual Reality Distraction on Pain and Anxiety During Dental Treatment in 5 to 8 Year Old Children, Journal of Clinical Pediatric Dentistry 2019;43:97-102. 31. Furman E, Jasinevicius TR, Bissada NF, et al. Virtual Reality Distraction for Pain Control During Periodontal Scaling and Root Planing Procedures, The Journal of the American Dental Association 2009;140:1508-16 doi:10.14219/jada.archive.2009.0102. 32. Schneider SM, Hood LE. Virtual Reality: A Distraction Intervention for Chemotherapy, Oncology nursing forum 2007;34:39-46 doi:10.1188/07.ONF.39-46.

The Virtual Reality Study Protocol Version 1.0

- 33. Gerardi M, Rothbaum BO, Ressler K, et al. Virtual reality exposure therapy using a virtual Iraq: Case report, *Journal of Traumatic Stress* 2008;21:209-13 doi:10.1002/jts.20331.
- 34. Parsons TD, Rizzo AA. Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: A meta-analysis, *Journal of Behavior Therapy and Experimental Psychiatry* 2008;39:250-61 doi:10.1016/j.jbtep.2007.07.007.
- 35. Botella C, Serrano B, Baños RM, et al. Virtual reality exposure-based therapy for the treatment of post-traumatic stress disorder: a review of its efficacy, the adequacy of the treatment protocol, and its acceptability, *Neuropsychiatr Dis Treat* 2015;11:2533-45 doi:10.2147/NDT.S89542.
- 36. Marco JH, Perpiñá C, Botella C. Effectiveness of cognitive behavioral therapy supported by virtual reality in the treatment of body image in eating disorders: One year follow-up, *Psychiatry Research* 2013;209:619-25 doi:10.1016/j.psychres.2013.02.023.
- 37. Litwin SP, Nguyen C, Hundert A, Stuart S, Liu D, Maguire B, Matava C, Stinson J. Virtual reality to reduce procedural pain during IV insertion in the pediatric emergency department: a pilot randomized controlled trial. The Clinical Journal of Pain. 2021 Feb 1;37(2):94-101.
- 38. Goldman RD, Behboudi A. Virtual reality for intravenous placement in the emergency department—a randomized controlled trial. European Journal of Pediatrics. 2021 Mar;180(3):725-31.
- 39. Chen YJ, Cheng SF, Lee PC, Lai CH, Hou IC, Chen CW. Distraction using virtual reality for children during intravenous injections in an emergency department: A randomised trial. Journal of clinical nursing. 2020 Feb;29(3-4):503-10.
- 40. Osmanlliu E, Trottier ED, Bailey B, Lagacé M, Certain M, Khadra C, Sanchez M, Thériault C, Paquin D, Côtes-Turpin C, Le May S. Distraction in the Emergency department using Virtual reality for INtravenous procedures in Children to Improve comfort (DEVINCI): a pilot pragmatic randomized controlled trial. Canadian Journal of Emergency Medicine. 2021 Jan;23(1):94-102.
- 41. Lambert V, Boylan P, Boran L, et al. Virtual reality distraction for acute pain in children, *The Cochrane database of systematic reviews* 2020;10 doi:10.1002/14651858.CD010686.pub2.
- 42. Czech O, Wrzeciono A, Rutkowska A, Guzik A, Kiper P, Rutkowski S. Virtual reality interventions for needle-related procedural pain, fear and anxiety—A systematic review and meta-analysis. Journal of clinical medicine. 2021 Jan;10(15):3248.
- 43. Chan A, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials, *Ann Intern Med* 2013;158:200-7 doi:10.7326/0003-4819-158-3-201302050-00583.
- 44. Hoffman HG, Rodriguez RA, Gonzalez M, et al. Immersive Virtual Reality as an Adjunctive Non-opioid Analgesic for Pre-dominantly Latin American Children With Large Severe Burn Wounds During Burn Wound Cleaning in the Intensive Care Unit: A Pilot Study, *Frontiers in human neuroscience* 2019;13 doi:10.3389/fnhum.2019.00262.
- 45. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational

The Virtual Reality Study Protocol Version 1.0

research informatics support, *Journal of Biomedical Informatics* 2009;42:377-81 doi:10.1016/j.jbi.2008.08.010.

- 46. Jay SM, Elliott C. Observation Scale of Behavioral Distress-Revised. Information procedures, definitions of behaviors, OSBD Interval Coding Form. 1986.
- 47. Jay SM, Elliott C. Behavioral observation scales for measuring children's distress: The effects of increased methodological rigor, *Journal of Consulting and Clinical Psychology* 1984;52:1106-7 doi:10.1037/0022-006X.52.6.1106.
- 48. Tucker CL, Slifer KJ, Dahlquist LM. Reliability and Validity of the Brief Behavioral Distress Scale: A Measure of Children's Distress During Invasive Medical Procedures, *J Pediatr Psychol* 2001;26:513-23 doi:10.1093/jpepsy/26.8.513.
- 49. Elliott CH, Jay SM, Woody P. An Observation Scale for Measuring Children's Distress During Medical Procedures, *J Pediatr Psychol* 1987;12:543-51 doi:10.1093/jpepsy/12.4.543.
- 50. Megel ME, Houser CW, Gleaves LS. Children's Responses to Immunizations: Lullabies as a Distraction, *Issues in Comprehensive Pediatric Nursing* 1998;21:129-45 doi:10.1080/014608698265456.
- 51. Noguchi LK. The Effect of Music Versus Nonmusic on Behavioral Signs of Distress and Self-Report of Pain in Pediatric Injection Patients, *J Music Ther* 2006;43:16-38 doi:10.1093/jmt/43.1.16.
- 52. Hartling L, Newton AS, Liang Y, et al. Music to Reduce Pain and Distress in the Pediatric Emergency Department: A Randomized Clinical Trial, *JAMA Pediatrics* 2013;167:826-35 doi:10.1001/jamapediatrics.2013.200.
- 53. Stevenson MD, Bivins CM, O'Brien K, et al. Child Life Intervention During Angiocatheter Insertion in the Pediatric Emergency Department, *Pediatric Emergency Care* 2005;21:712 doi:10.1097/01.pec.0000186423.84764.5a.
- Jay SM, Ozolins M, Elliott CH, et al. Assessment of children's distress during painful medical procedures, *Health Psychology* 1983;2:133-47 doi:10.1037/0278-6133.2.2.133.
- 55. von Baeyer CL. Children's self-report of pain intensity: what we know, where we are headed, *Pain research & management* 2009;14:39.
- 56. Miró J, Castarlenas E, de la Vega R, et al. Validity of three rating scales for measuring pain intensity in youths with physical disabilities, *Eur J Pain* 2016;20:130-7 doi:10.1002/ejp.704.
- 57. Castarlenas E, Jensen MP, von Baeyer CL, et al. Psychometric Properties of the Numerical Rating Scale to Assess Self-Reported Pain Intensity in Children and Adolescents: A Systematic Review, *Clin J Pain* 2017;33:376-83 doi:10.1097/AJP.00000000000406.
- Castarlenas E, Miró J, Sánchez-Rodríguez E. Is the verbal numerical rating scale a valid tool for assessing pain intensity in children below 8 years of age? *J Pain* 2013;14:297-304 doi:10.1016/j.jpain.2012.12.004.
- 59. McKinley S, Coote K, Stein-Parbury J. Development and testing of a Faces Scale for the assessment of anxiety in critically ill patients, *Journal of Advanced Nursing* 2003;41:73-9 doi:10.1046/j.1365-2648.2003.02508.x.
- 60. Spielberger CD, Sydeman SJ. State-trait anxiety inventory and state-trait anger expression inventory. Hillsdale, NJ: Lawrence Erlbaum Associates 1994:292-321.

- 61. Baxter AL, Watcha MF, Baxter WV, et al. Development and validation of a pictorial nausea rating scale for children. Pediatrics 2011;127:1542.
- 62. Gold JI, Mahrer NE. Is Virtual Reality Ready for Prime Time in the Medical Space? A Randomized Control Trial of Pediatric Virtual Reality for Acute Procedural Pain Management, Journal of pediatric psychology 2018;43 doi:10.1093/jpepsy/jsx129.
- 63. Hoffman HG, Patterson DR, Seibel E, et al. Virtual reality pain control during burn wound debridement in the hydrotank, The Clinical journal of pain 2008;24 doi:10.1097/AJP.0b013e318164d2cc.
- Jac ric psy seibel E, c nydrotank, The Ji8164d2ce. Committee of Medical. rw.icmje.org/recommendat. rfning-the-role-of-authors-and-64. ICMJE. International Committee of Medical Journal Editors. 2017. Available: http://www.icmje.org/recommendations/browse/roles-andresponsibilities/defining-the-role-of-authors-and-contributors.html [Accessed 03 Aug 2021].

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 25 of 55




# VR Game Menu Easy/Novice

| Title                  | Category              | Content  | Controller  | Comments   |
|------------------------|-----------------------|--|---|--|
| Henry                  | Immersive<br>12 min   | Henry is the story of a<br>little hedgehog on his<br>birthday.   | None  | Fun, magical, some<br>movement                               |
| YouTube                | Immersive<br>Passive  | Watch YouTube videos<br>in VR.                                   | Use the front trigger to browse<br>and choose videos  | Some videos might not be<br>VR<br>360 videos can be dizzying |
| Myth: A Frozen<br>Tale | Immersive<br>8 min    | Watch the elemental<br>spirits of air, fire, water<br>and earth. | None  | Some movement,<br>Magical creatures                          |
| Color Space            | Interactive           | A virtual reality coloring<br>book with sound.                   | <ul> <li>Left controller is the paint<br/>pallet</li> <li>Right controller selects color</li> </ul>   | Calming, relaxing<br>No movement                             |
| Tilt Brush             | Interactive           | Paint your own 3D<br>world!                                      | <ul> <li>Left controller: art tools</li> <li>Left joy-stick flips through art tools</li> <li>Right controller selects tool and draws</li> </ul> | Calming, relaxing<br>No movement                             |
| Bonfire                | Interactive<br>15 min | You've crash-landed on<br>an alien planet and try<br>to survive. | Front Trigger<br>Right hand joystick  | Rated: 10+<br>Some movement,<br>Fight a giant slug           |

\*Child can be lying down for any of these games

# VR Game Menu Experienced

| Title                                  | Category  | Content   | Controller   | Comments  |
|--|---|---|--|---|
| Jurassic World                         | Immersive<br>7 min (Blue)<br>3 min (Apatosarus)       | Watch Blue the dinosaur interact<br>with other dinosaurs!<br>* Choose Blue first then<br>Apatosaurus  | Front trigger to choose video.<br>Use any button to go back to<br>main menu  | Be careful, you will interact<br>with a T-rex!<br>Can be lying down.  |
| Tetris Effects                         | Interactive   | Tetris like you've never seen it, or<br>heard it, or felt it before!<br>* Play Journey Mode   | <ul> <li>L hand joy-stick moves block</li> <li>Right hand A or B to change<br/>orientation of the block</li> <li>Right hand trigger to change<br/>block option</li> </ul>  | Some movement,<br>Lights and music.<br>Can be lying down.   |
| Fruit Ninja                            | Interactive   | Slice through flying fruits!<br>* Only Arcade game can be played  | Swipe fruits with dominant<br>hand controller.   | Not a lot of movement,<br>Only the flying fruits.<br>Need to be sitting up.   |
| Moss                                   | Interactive<br>Requires knowledge<br>of VR or garning | Action-adventure puzzle game.<br>Help a young mouse explore a<br>magical world.<br>*Hint: Use index trigger to drag<br>blue glowing boxes   | Left hand joystick to move<br>Right hand A to jump<br>Right B to hit/attack<br>Right hand A&B to avoid<br>Double B to go back to menu  | There will be puzzles you'll<br>have to figure out!<br>Need to be sitting up<br>straight.   |
| Vader Immortal<br>I, II and III<br>For | Interactive<br>Requires knowledge<br>of VR or ganning | Step into a galaxy far far away!<br>Episode I: hone light saber skills<br>Episode II: Learn to use the force<br>Episode III: Master the skills of the<br>Jedi<br>*Light saber dojo in each episode<br>is very fun!<br>y - http://bmjopen.bmj.co | <ul> <li>Joy stick to hover where to<br/>move</li> <li>Left joy stick when in the<br/>dojo.</li> <li>To use the force: press the<br/>grab trigger and hover over<br/>the object, you can move it<br/>towards you or throw/aim<br/>away</li> <li>Hint: check your belt you<br/>may have objects (e.g. light<br/>saber)</li> </ul> | Need to be sitting up<br>straight<br>Rated: Teen<br>- Star Wars graphics<br>- Fighting with the force<br>- Need to be able to sit up<br>straight<br>- Lots of virtual<br>movement<br>es.xhtml |





#### A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# **Pre-Screening**

| Date and Time of Triage                   | //<br>dd mmm yyyy<br>:<br>(24 hour clock)  |
|---|--|
| Child's Age                               | years  |
| Child's Sex                               | E Female Male  |
| Was the family approached for this study? | Yes No   |
| If NO, specify reason and STOP HERE.      | <ul> <li>Family refused overall consent to be approached for research</li> <li>Legal guardian not present</li> <li>RA busy with another study</li> <li>Did not meet eligibility criteria, specify</li> <li>Other, Specify</li> </ul> |
| If YES, continue to Eligibility.          | 4  |



| 2  |
|--|
|  |
| 3  |
| 4  |
| -  |
| 4<br>5<br>7<br>8<br>9<br>10  |
| 6  |
| 7  |
| <i>'</i>   |
| 8  |
| 9  |
| 10   |
| 10   |
| 11   |
| 12   |
| 12   |
| 15   |
| 14   |
| 15   |
| 16   |
| 10   |
| 17   |
| 18   |
| 10   |
| 17   |
| <ol> <li>13</li> <li>14</li> <li>15</li> <li>16</li> <li>17</li> <li>18</li> <li>19</li> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> <li>26</li> <li>27</li> <li>28</li> <li>29</li> <li>30</li> <li>31</li> </ol> |
| 21   |
| 22   |
| 22   |
| 23   |
| 24   |
| 25   |
| 25   |
| 26   |
| 27   |
| 27   |
| 28   |
| 29   |
| 30   |
| 50   |
| 31   |
| 32   |
| 32<br>33   |
|  |
| 34<br>35<br>36<br>37   |
| 35   |
| 20   |
| 30   |
| 37   |
| 37<br>38   |
|  |
| 39   |
| 40   |
| 41   |
|  |
| 42   |
| 43   |
| 44   |
|  |
| 45   |
| 46   |
| 47   |
|  |
| 48   |
| 49   |
| 50   |
|  |
| 51   |
| 52   |
| 53   |
|  |
| 54   |
| 55   |
|  |
| 56   |
| 57   |
| 58   |
|  |
| 59   |

60

| A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children |
|--|
| The VR Study   |

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# Eligibility

| Was verbal consent for screening obtained from the family? | 🗌 Yes | 🗌 No |
|--|-------|------|
|  |       |      |

## **Inclusion Criteria**

| 1. Child aged 6-17 years                                  | 🗌 Yes | 🗌 No |  |  |
|---|-------|------|--|--|
| 2. Requires IV placement                                  | 🗌 Yes | 🗌 No |  |  |
| 3. Will receive topical anesthetic cream for IV placement | 🗌 Yes | 🗌 No |  |  |
|   |       |      |  |  |
| Exclusion Criteria  |       |      |  |  |

## **Exclusion Criteria**

| 1.    | Medically unstable (i.e. CTAS 1, requires immediate IV insertion)   | 🗌 Yes | 🗌 No |
|-------|---|-------|------|
| 2.    | Unconscious or not fully alert  | 🗌 Yes | 🗌 No |
| 3.    | Visual, auditory or cognitive or mental health issues precluding safe interaction with the VR intervention  | 🗌 Yes | 🗌 No |
| 4.    | Conditions that could be exacerbated by the VR environment (as reported by the family)<br>a. <i>current</i> symptomatic nausea / vomiting / dizziness / migraine<br>b. <i>history</i> of psychosis / hallucinations / epilepsy  | 🗌 Yes | 🗌 No |
| 5.    | <ul> <li>Presence of an infection / injury which could contaminate the VR intervention equipment (as determined by the healthcare team) including but not limited to a. open wounds / infections of the head and neck area</li> <li>b. suspected or confirmed methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) colonization</li> </ul> | 🗌 Yes | No   |
| 6.    | Screens positive for 'influenza-like illness' (ILI) as per the current SCH ED screening criteria  | 🗌 Yes | 🗌 No |
| 7.    | Child or Parental language barrier precluding the ability to understand and complete study assessments, in the absence of a native language translator  | 🗌 Yes | 🗌 No |
| 8.    | Previous enrollment (of child OR parent) in this study  | 🗌 Yes | 🗌 No |
| ls th | ne family eligible for the study?   | Yes   | 🗌 No |



| REB #: Pro00095418                                    | 3 #: Pro00095418 Screening ID  |   |
|---|--|---|
| PI: Dr. Samina Ali                                    | VR   | // <u>2</u> 0/<br>dd mmm yyyy   |
| nformed Consent                                       |  |   |
| as written informed cons                              | sent been obtained from the <b>parent/ legal gua</b>   | rdian? 🗌 Yes 🗌  |
| <u>NO,</u>  |  |   |
| Specify reason and STC                                | P HERE.  | <ul> <li>Declined consent</li> <li>Declined assent</li> <li>Other, please specify</li> </ul>  |
| <u>'YES,</u>  |  |   |
| Specify the date and tim                              | e of Informed Consent:   | //<br>dd mmm yyyy<br>:<br>(24 hour clock)   |
| Has a copy of the signed                              | informed consent been given to the family?   | Yes No; specify:  |
| Has written assent been                               | obtained from the <b>child</b> ?   | <ul> <li>Yes</li> <li>No; specify:</li> <li>No, but verbal assent was obtained and documented</li> <li>Not required; child &lt; 7y</li> </ul> |
| Has a copy of the signed                              | d assent been given to the family?   | Yes No; specify:  |
| Note: Consent only needs entire duration of the study | nsent been provided by the <b>clinical nurse</b> ?<br>to be provided by the clinical nurse once for the<br>y (for all 80-90 participants). If consent has not<br>with the clinical nurse, make sure a signed copy<br>ment. | Yes No; specify:  |
| Clinical Nurse Study ID I                             | Number:  |   |



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# Randomization

If the child satisfies the inclusion/ exclusion criteria and written informed consent has been provided, please RANDOMIZE the participant by clicking on the Randomize button below:

| Study Arm | <u> </u> | <ul><li>□ VR Intervention</li><li>□ Standard Care</li></ul> |
|-----------|----------|---|
|           |          |   |
|           |          |   |
|           |          |   |
|           |          |   |
|           |          |   |
|           |          |   |
|           |          |   |
|           |          |   |
|           |          |   |
|           |          |   |
|           |          |   |
|           |          |   |



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 Screening ID |    | Enrolment Date            |
|---------------------------------|----|---------------------------|
| PI: Dr. Samina Ali              | VR | // <u>20</u><br>ddmmmyyyy |

# **Demographics & History**

### **Demographics**

| Parent/ Caregiver relationship to child                       | Mother                           |
|---|----------------------------------|
|   | Father                           |
|   | Other; specify:                  |
| Parent / Caregiver Age  | years; or 🗌 Prefer not to answer |
| Parent / Caregiver Sex  | E Female                         |
|   | Male                             |
| Parent / Caregiver Highest level of Education                 | Elementary School                |
|   | High School or some High School  |
|   | Diploma/ Certificate             |
|   | Some Post-Secondary/ University  |
|   | University/ Professional Degree  |
|   | Decline to answer                |
| First three digits of postal code                             | (1 <sup>st</sup> 3 digits ONLY)  |
| Do you identify your child as a member of an ethnic minority? | Yes                              |
|   | No                               |
| · L   | )                                |
| Medical History   |                                  |

## **Medical History**

| Was your child born prematurely?                            | Yes   |
|---|-------|
|   | No    |
| If yes, at how many weeks gestation?                        | weeks |
| Has your child ever been to the Emergency Department before | ☐ Yes |
| today?  | 🗌 No  |
| If yes, how many times:                                     | times |
| Has your child ever been hospitalized?                      | ☐ Yes |
|   | 🗌 No  |
| If yes, how many times:                                     | times |
| Has your child ever had a needle poke in their vein to draw | ☐ Yes |
| blood or put in an intravenous (IV) line?                   | 🗌 No  |



| REB #: Pro00095418   | Screening ID   |  |   | Enrolment Date   |
|--|--|--|---|--|
| PI: Dr. Samina Ali   | VR   |  |   | // <u>2 0</u><br>dd mmm yyyy   |
| more than one occurrenc<br>recent event) Choose a n  | s your child during the proc<br>e, ask the parent to recall to<br>number between 1 and 5 that<br>tress where 1 indicates 'no<br>d as possible' | he most<br>at best                               | □ 2<br>□ 3<br>□ 4                           | stress at all)<br>stressed as possible)  |
| Child Experience with<br>Has your child played wit<br>following devices before t               | h/ used any of the   | ☐ Gaming<br>(ex. Xbo:<br>☐ Virtual R<br>(ex. Ocu | console<br>k, Nintendo, F<br>eality (VR) de | evice<br>t, Samsung Gear VR,   |
| If yes, how frequently?  |  | 7  |   |  |
| iPad/ iPod/ iPhone /<br>Tablet:  | Gaming console   | VR device  |   | Robot  |
| <ul> <li>hours/ week</li> <li>Less than Once per week</li> <li>Less than 5 times in</li> </ul> | <ul> <li>hours/ week</li> <li>Less than Once per week</li> <li>Less than 5 times in total</li> </ul>   | <br>☐ Less tha<br>week                           | ours/ week<br>n Once per<br>n 5 times in    | <ul> <li>hours/ week</li> <li>Less than Once per week</li> <li>Less than 5 times in total</li> </ul> |



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date             |
|--------------------|--------------|----------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>ddmmyyyy |


## **PRE-Procedure: Child Scores**

NOTE: Begin the video recorder (iPad) approximately 5 minutes before the start of the IV procedure, and stop the recording 5 minutes after the end of the procedure.

#### **Baseline Scores: Child**

| Heart Rate (record from Triage)  | bpr     | n             |       |
|--|---------|---------------|-------|
| Time pre-procedure scores collected  | dd      | /<br>mmm<br>: | /<br> |
|  | (24 hou | ur clock)     |       |
| Pain Score: verbal Numerical Rating Scale (vNRS)<br>"On a scale of 0 to 10, where 0 is no pain and 10 is the worst<br>pain you can imagine, what is your pain level now?"            | / 10    | )             |       |
| Distress Score: Numerical Rating Scale<br>"On a scale of 0 to 10, where 0 is no distress and 10 is the<br>most distress you can imagine having, what is your distress<br>level now?" | / 10    | )             |       |

"These faces are showing different amounts of being scared. This face [point to the left-most face] is not scared at all, this face is a little bit more scared [point to the second face from left], a bit more scared [sweep finger along scale], right up to the most scared possible [pint to the last face on the right]. Have a look at these faces and choose the one that shows how scared you are right now."







A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# PRE-Procedure: Parent / Caregiver STAI Questionnaire

We would ask that you complete the following questions as they relate to your feelings about your child's upcoming IV procedure, today. A number of statements which people have used to describe themselves are given below. Read each statement and then circle the appropriate number to indicate how you feel right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time on any one statement but give the answer which seems to describe your feelings best.

|     | Not at all Somewhat Moderately so Very much so   |   |  |  |   |
|-----|--|---|--|--|---|
|     |  |   |  |  |   |
| 1.  | I feel calm  | 1   | 2  | 3  | 4   |
| 2.  | I feel secure  | 1   | 2  | 3  | 4   |
| 3.  | I am tense   | 1   | 2  | 3  | 4   |
| 4.  | I feel strained  | 1   | 2  | 3  | 4   |
| 5.  |  | 1   | 2  | 3  | 4   |
| 6.  | I feel upset   | 1   | 2  | 3  | 4   |
| 7.  | I am presently worrying over possible misfortunes  | 1   | 2  | 3  | 4   |
| 8.  |  | 1   | 2  | 3  | 4   |
| 9.  | I feel frightened  | 1   | 2  | 3  | 4   |
| 10. | I feel comfortable   | 1   | 2  | 3  | 4   |
| 11. | I feel self-confident  | 1   | 2  | 3  | 4   |
| 12. |  | 1   | 2  | 3  | 4   |
| 13. | I am jittery   | 1   | 2  | 3  | 4   |
| 14. | I feel indecisive  | 1   | 2  | 3  | 4   |
| 15. | I am relaxed   | 1   | 2  | 3  | 4   |
| 16. | I feel content   | 1   | 2  | 3  | 4   |
| 17. | I am worried   | 1   | 2  | 3  | 4   |
| 18. | I feel confused  | 1   | 2  | 3  | 4   |
| 19. | I feel steady  | 1   | 2  | 3  | 4   |
| 20. | I feel pleasant  | 1   | 2  | 3  | 4   |
|     | <ol> <li>2.</li> <li>3.</li> <li>4.</li> <li>5.</li> <li>6.</li> <li>7.</li> <li>8.</li> <li>9.</li> <li>10.</li> <li>11.</li> <li>12.</li> <li>13.</li> <li>14.</li> <li>15.</li> <li>16.</li> <li>17.</li> <li>18.</li> <li>19.</li> </ol> | 2.       I feel secure.         3.       I am tense.         4.       I feel strained.         5.       I feel at ease.         6.       I feel upset.         7.       I am presently worrying over possible misfortunes.         8.       I feel satisfied.         9.       I feel frightened.         10.       I feel comfortable.         11.       I feel self-confident.         12.       I feel nervous.         13.       I am jittery.         14.       I feel indecisive.         15.       I am relaxed.         16.       I feel content.         17.       I am worried.         18.       I feel confused.         19.       I feel steady. | Not at all         Somewhat         Moderately so         Very much so           1         I feel calm | Not at all         Somewhat         Moderately so         Very much so           1         I feel calm | Not at all         Somewhat         Moderately so         Very much so           1         I feel calm.         1         2         3           2         I feel secure.         1         2         3           3         I am tense.         1         2         3           4         I feel strained.         1         2         3           5         I feel at ease.         1         2         3           6         I feel ypset.         1         2         3           7         I am presently worrying over possible misfortunes.         1         2         3           8         I feel satisfied.         1         2         3           9         I feel comfortable.         1         2         3           10         I feel self-confident.         1         2         3           11         I feel nervous.         1         2         3           12         I feel indecisive.         1         2         3           13         I am jittery.         1         2         3           14         I feel indecisive.         1         2         3           15         I am relaxed. <t< td=""></t<> |



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date            |
|--------------------|--------------|---------------------------|
| PI: Dr. Samina Ali | VR           | // <u>20</u><br>ddmmmyyyy |

# **DURING-Procedure**

- Start the iPad video recording approximately 5 minutes prior to the start of the procedure.
- For children randomized to the VR group: Immediately after PRE-procedure scores and STAI are completed, research assistant will set up the VR equipment.
- The staff ED nurse will then begin the IV set-up

| Start time of IV procedure:   |         | _/         |      |
|---|---------|------------|------|
| (Defined as the time the staff nurse begins to clean the IV site)   | dd      | mmm        | уууу |
|   |         | _:         | _    |
|   | (24 11  | our clock) |      |
| End time of IV procedure/ attempt: 🚫  |         |            |      |
|   |         | /          | /    |
| (Defined as the last point of contact by the staff nurse (ex. taping<br>cannula in place with or without arm board, wrapping arm with | dd      | mmm        | уууу |
| gauze and taping the gauze in place)  | <b></b> | _:         | _    |
|   | (24 h   | our clock) |      |

| Position of Child during IV attempt:  | Sitting up Lying down (supine)  |  |  |
|---|---|--|--|
| Location of first IV attempt:   | <ul> <li>Antecubital Fossa – RIGHT</li> <li>Antecubital Fossa – RIGHT</li> <li>Dorsum hand – RIGHT</li> <li>Dorsum hand – LEFT</li> <li>Other, specify</li> </ul> |  |  |
| Was the first IV placement attempt successful?  |   |  |  |
| <ul> <li>If NO, how many attempts, in total, were made for the<br/>IV during this 'episode'?</li> </ul> | attempts  |  |  |
| Was an IV successfully placed during this 'episode'?  | Yes No  |  |  |

| Any adverse events or side effects?  | Yes No  |
|--|---|
| Do not suggest any AEs to the participant; Instead, ask more general questions such as "how are you feeling?" or "are you having any side effects?" or "are you feeling any different than before?", and let the child answer spontaneously. | If " <b>YES</b> ", complete a separate entry for each AE on the AE Form |



| REB #: Pro00095418   |   | Screening ID  |  | Enrolment Date   |
|--|---|---|--|--|
| PI: Dr. Samina Ali   | VR  |   |  | // <u>2</u> 0/<br>dd mmm yyyy  |
| <b>IMEDIATELY PO</b><br>OTE: Post-procedure so<br>ocedure is complete:                             | cores/ questionnair   |   | -  | <u>possible</u> after the  |
| ost-procedure Score  | es: Child   |   |  |  |
| Time post-procedure sc   | ores collected  |   |  | dd mmm yyyy  |
|  | 0   |   |  | ::<br>(24 hour clock)  |
| Pain Score: verbal Num<br>'On a scale of 0 to 10, v<br>magine, what was your                       | where 0 is no pain a  | and 10 is the wors  | t pain you can                                       | / 10   |
| Distress Score: Numerie<br>"On a scale of 0 to 10, v<br>you can imagine having<br><u>IV poke</u> " | where 0 is no distre  | ess and 10 is the r   |  | / 10   |
| scared at all, this face is<br>[sweep finger along sca   | ng different amoun<br>s a little bit more sc<br>le], right up to the r                      | ts of being scared<br>ared [point to the<br>most scared possi | second face from<br>ole [pint to the la              | to the left-most face] is not<br>in left], a bit more scared<br>ist face on the right]. Have<br>ing the needle / IV poke." |
|  |   |   |  |  |
| call that feeling of being<br>all, who feel a little bit n   | felt like you were g<br>sick to the stomac<br>auseated, who feel<br>ble to feel." [Point to | joing to throw up b<br>h nausea. These<br>even more nause     | efore? How did<br>aces show child<br>ated, and these | your tummy feel then? We<br>ren who feel no nausea at<br>are children who have the<br>.] "Which face is more like          |



| REB #: Pro00095418     | Screening ID  | Enrolment Date  |
|------------------------|---|---|
| PI: Dr. Samina Ali     | VR  | / / <u>2 0</u><br>ddmmmyyyy   |
|                        |   |   |
|                        |   |   |
|                        | were you with the IV start today, on a scale of 1 to a at all happy" and 5 means "Very happy"?        | 5,     1 "Not at all happy<br>  2<br>  3<br>  4<br>  5 "Very happy"   |
|                        | where 1 means "Not at all happy" and 5 means appy were you <u>with the pain treatment</u> for your IV | <ul> <li>☐ 1 "Not at all happy"</li> <li>☐ 2</li> <li>☐ 3</li> <li>☐ 4</li> <li>☐ 5 "Very happy"</li> </ul> |
| Did the [distraction / | toys / VR goggles] help you today?  | <ul> <li>Yes, it helped</li> <li>No, it didn't help</li> <li>I'm not sure</li> </ul>                        |
|                        | t an IV or needle poke again, would you want to us<br>n / toys / VR goggles] again?                   | se<br>Yes, I would<br>No, I wouldn't<br>I'm not sure  |
|                        | ne why/ why not?  |   |

As soon as possible after completion of procedure, research assistant to give:

1. Post-Procedure Parent STAI and Satisfaction Questionnaire to parent/ caregiver

2. Nurse Satisfaction Questionnaire to staff ED nurse





 A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# **POST-Procedure:** Parent / Caregiver STAI Questionnaire

We would ask that you complete the following questions as they relate to your feelings about your child's IV procedure that just happened. A number of statements which people have used to describe themselves are given below. Read each statement and then circle the appropriate number to indicate how you feel right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time on any one statement but give the answer which seems to describe your feelings best.

| 10       |     | 13   |   |   |   |   |
|----------|-----|--|---|---|---|---|
| 19<br>20 |     | I4<br>Not at all Somewhat Moderately so Very much so |   |   |   |   |
| 20       |     |  |   |   |   |   |
| 22<br>23 | 1.  | I feel calm  | 1 | 2 | 3 | 4 |
| 24       | 2.  | I feel secure  | 1 | 2 | 3 | 4 |
| 25<br>26 | 3.  | I am tense   | 1 | 2 | 3 | 4 |
| 27<br>28 | 4.  | I feel strained                                      | 1 | 2 | 3 | 4 |
| 29<br>30 | 5.  | I feel at ease                                       | 1 | 2 | 3 | 4 |
| 31       | 6.  | I feel upset   | 1 | 2 | 3 | 4 |
| 32<br>33 | 7.  | I am presently worrying over possible misfortunes    | 1 | 2 | 3 | 4 |
| 34<br>35 | 8.  | I feel satisfied                                     | 1 | 2 | 3 | 4 |
| 36       | 9.  | I feel frightened                                    | 1 | 2 | 3 | 4 |
| 37<br>38 | 10. | I feel comfortable                                   | 1 | 2 | 3 | 4 |
| 39<br>40 | 11. | I feel self-confident                                | 1 | 2 | 3 | 4 |
| 41       | 12. | I feel nervous                                       | 1 | 2 | 3 | 4 |
| 42<br>43 | 13. | I am jittery   | 1 | 2 | 3 | 4 |
| 44<br>45 | 14. | I feel indecisive                                    | 1 | 2 | 3 | 4 |
| 46       | 15. | I am relaxed   | 1 | 2 | 3 | 4 |
| 47<br>48 | 16. | I feel content                                       | 1 | 2 | 3 | 4 |
| 49<br>50 | 17. | I am worried   | 1 | 2 | 3 | 4 |
| 51       | 18. | I feel confused                                      | 1 | 2 | 3 | 4 |
| 52<br>53 | 19. | I feel steady  | 1 | 2 | 3 | 4 |
| 54<br>55 | 20. | I feel pleasant                                      | 1 | 2 | 3 | 4 |



| REB #: Pro00095418           |                            | Screening ID                          |                       | Enrolment Date                |
|------------------------------|----------------------------|---------------------------------------|-----------------------|-------------------------------|
| PI: Dr. Samina Ali           | VR                         |                                       | -                     | / / <u>2 0</u><br>ddmmmy      |
| OST-Procedure:               | Caregiver Sati             | sfaction Que                          | stionnaire            |                               |
| ) Please rate your ov        | verall satisfaction        | with your child's                     | IV start:             |                               |
| Very<br>Dissatisfied<br>1    | Dissatisfied<br>2          | Neutral<br>3<br>□                     | Satisfied<br><b>4</b> | Very<br>Satisfied<br><b>5</b> |
| Please Explain: _            |                            |                                       |                       |                               |
|                              |                            |                                       |                       |                               |
|                              | 0                          | 0                                     |                       |                               |
| ) Please rate your sa        | atisfaction with the       | management of                         | your child's pain f   | for their IV start:           |
| Very<br>Dissatisfied<br>1    | Dissatisfied<br><b>2</b>   | Neutral<br>3                          | Satisfied<br><b>4</b> | Very<br>Satisfied<br><b>5</b> |
|                              |                            |                                       |                       |                               |
| Please Explain: _            |                            |                                       | 4                     |                               |
|                              |                            |                                       | <u> </u>              |                               |
|                              |                            |                                       |                       |                               |
| Would you use the<br>future? | same methods to            | manage your ch                        | ild's pain from nee   | edle pokes in the             |
| Yes No                       |                            |                                       |                       |                               |
| Why / Why not?               |                            |                                       |                       |                               |
|                              |                            |                                       |                       |                               |
|                              |                            |                                       |                       |                               |
|                              |                            |                                       |                       |                               |
|                              | Thank you for you<br>it is | r participation in<br>very much appre |                       | ly,                           |
|                              |                            |                                       |                       |                               |
| VR Study CRF                 | N N                        | Version July 15. 20                   | 20                    | Page <b>13</b> of <b>2</b>    |



| REB #: Pro00095418 |  |   | Screening ID  |                            | Enrolment   | Date              |
|--------------------|--|---|---|----------------------------|---|-------------------|
| PI:                | Dr. Samina Ali   | VR  |   | _                          | /<br>ddmmm  | / <u>2 0</u><br>  |
| lu                 | rse Satisfactio  | on Questionnair   | e (VR Group)  |                            |   |                   |
| 1)                 | Overall, how easy  | or difficult was it to pe   | erform the IV inse  | rtion for this child?      |   |                   |
|                    | Very Easy<br>1   | Easy<br>2   | Neutral<br>3  | Difficult                  | Very Difficul<br><b>5</b>                             | lt                |
| 2)                 | Please rate your s   | atisfaction with this ch  | nild's IV start:  |                            |   |                   |
|                    | Very<br>Dissatisfied<br>1  | Dissatisfied  | Neutral   | Satisfied<br><b>4</b><br>□ | Very<br>Satisfied<br>5                                |                   |
| 3)                 | from IV insertion in<br>Yes<br>No  |   | R.  | •                          |   | SS                |
| 1)                 | Could you please   | rate the following on a   | a scale of 1-5, whe   | ere 1= Not at all an       |   | _                 |
|                    | Your willingness to<br>pain and distress i<br>The degree to whi<br>The degree to whi | action with the Virtual<br>o use the VR device to<br>n the future<br>ch the VR device impr<br>ch the VR <b>improved</b> y<br>ch the VR <b>disrupted</b> y | o manage another<br>roved the child's e<br>your ability to inse | child's IV                 | $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | 5<br>  <br>  <br> |
| 5)                 |  | that was used during<br>imately how much tim  | •   |                            |   | e IV?             |
|                    |  | also that you would lik   | e to tell us todav  | about vour experi          | ence inserting ar                                     | n IV              |



| A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children:<br>The VR Study |  |                           |  |
|---|--|---------------------------|--|
| REB #: Pro00095418  | Screening ID   | Enrolment Date            |  |
| PI: Dr. Samina Ali  | VR   | // <u>2 0</u><br>dd mmm y |  |
| 7) How many years of  | of practice do you have as a nurse (all settings)?         | N/A                       |  |
| 8) How many years o   | of practice do you have as a nurse in the ED?              | N/A                       |  |
| 9) Please indicate th   | e amount of time spent in the pediatric emergency dep      | artment (PED):            |  |
|   |  |                           |  |
|   | ny time is spent in the pediatric ED                       |                           |  |
|   | my time is spent in the pediatric ED                       |                           |  |
|   | my time is spent in the pediatric ED                       |                           |  |
| ∐ 76-100% c   | of my time is spent in the pediatric ED                    |                           |  |
|   |  |                           |  |
|   | ur position if other than attending ED nurse (e.g., IV nu  | rse, attending ED         |  |
| physician, residen  | it, physician or nurse from other service [specify], etc): |                           |  |
|   |  |                           |  |
|   | /  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   | Thank You!!  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  |                           |  |
|   |  | <b>_</b> •·               |  |
| VR Study CRF  | Version July 15, 2020                                      | Page 15 of 2              |  |



|  | EB #: Pro00095418 Screening ID  |  |   | E                     | Enrolment              | Date                                 |                    |
|--|---|--|---|-----------------------|------------------------|--------------------------------------|--------------------|
| PI: Dr. Sam  | ina Ali   | VR   |   | -                     | dd                     | /<br>mmm                             | / <u>2 0</u><br>yy |
| Nurse S  | Satisfactio   | n Questionnai  | re (Standard (  | Care Group)           |                        |                                      |                    |
| I) Overall   | , how easy or   | difficult was it to pe   | erform the IV insert  | tion for this child?  | ?                      |                                      |                    |
| Vei  | ry Easy   | Easy   | Neutral   | Difficult             | Ver                    | ry Difficul                          | t                  |
|  |   | 2  | 3<br>□  | 4                     |                        | 5<br>□                               |                    |
| 2) Please  | rate your sat   | isfaction with this ch   | ild's IV start:   |                       |                        |                                      |                    |
|  | Very  |  |   |                       | _                      | Very                                 |                    |
| Diss   | satisfied<br><b>1</b>   | Dissatisfied <b>2</b>  | Neutral<br><b>3</b>   | Satisfied<br><b>4</b> | S                      | Satisfied<br><b>5</b>                |                    |
|  |   | Ĺ  | o Č   |                       |                        |                                      |                    |
| ) Could  | you please rat  | te the following on a  | scale of 1-5, whe   | re 1= Not at all a    | nd <mark>5=Ve</mark> i | ry much                              |                    |
|  |   |  |   | 1                     | 2                      | 3 4                                  | 5                  |
| Your wi  | illingness to u   | tion with the pain ma<br>se a similar pain ma<br>in and distress in the              | anagement plan to   | _                     |                        |                                      |                    |
| anothei  | •   |  |   |                       |                        |                                      |                    |
|  | 0   | the pain manageme  | ent plan improved   | the child's           |                        |                                      |                    |
| The deg<br>experie   | nce<br>gree to which  | the pain management  |   |                       |                        |                                      |                    |
| The dee<br>experie<br>The dee<br>to inser  | nce<br>gree to which<br>t the IV<br>gree to which   |  | ent plan <b>improved</b>  | l your ability        |                        |                                      |                    |
| The deg<br>experie<br>The deg<br>to inser<br>The deg<br>to inser<br>5) Did the<br>the time | nce<br>gree to which<br>t the IV<br>gree to which<br>t the IV<br>Standard of<br>e required to i | the pain management<br>the pain management<br>Care pain management<br>insert the IV? | ent plan <b>improved</b><br>ent plan <b>disrupted</b><br>nent plan that was | I your ability        |                        |                                      | L<br>D<br>Se       |
| The deg<br>experie<br>The deg<br>to inser<br>The deg<br>to inser<br>5) Did the<br>the time | nce<br>gree to which<br>t the IV<br>gree to which<br>t the IV<br>Standard of<br>e required to i | the pain manageme<br>the pain manageme<br>Care pain managen                          | ent plan <b>improved</b><br>ent plan <b>disrupted</b><br>nent plan that was | I your ability        |                        | L L<br>L L<br>re increas<br>minutes) | L<br>L<br>Se       |



| <ul> <li>7) How many years of practice do you have as a nurse (all settings)? N/A</li> <li>8) How many years of practice do you have as a nurse in the ED? N/A</li> <li>9) Please indicate the amount of time spent in the pediatric emergency department (PED):</li> <li>0-25% of my time is spent in the pediatric ED</li> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> </ul>   | dd       mmm       yy         7) How many years of practice do you have as a nurse (all settings)?       N/A         8) How many years of practice do you have as a nurse in the ED?       N/A         9) Please indicate the amount of time spent in the pediatric emergency department (PED):       N/A         9) Please indicate the amount of time spent in the pediatric ED       0-25% of my time is spent in the pediatric ED         26-50% of my time is spent in the pediatric ED       51-75% of my time is spent in the pediatric ED         10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc):         Thank You!! | REB #: Pro00095418    | Screening ID  | Enrolment Date   |
|---|---|-----------------------|---|------------------|
| <ul> <li>B) How many years of practice do you have as a nurse in the ED? N/A</li> <li>Please indicate the amount of time spent in the pediatric emergency department (PED):</li> <li>0-25% of my time is spent in the pediatric ED</li> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> <li>10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc):</li> </ul> | 8) How many years of practice do you have as a nurse in the ED? N/A 9) Please indicate the amount of time spent in the pediatric emergency department (PED): <ul> <li>0-25% of my time is spent in the pediatric ED</li> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> </ul> 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!   | PI: Dr. Samina Ali    | VR  |                  |
| <ul> <li>9) Please indicate the amount of time spent in the pediatric emergency department (PED):</li> <li> <ul> <li>0-25% of my time is spent in the pediatric ED</li> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> </ul> </li> <li>10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc):</li> <li>Thank You!!</li> </ul>                                | <ul> <li>9) Please indicate the amount of time spent in the pediatric emergency department (PED):</li> <li>0-25% of my time is spent in the pediatric ED</li> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc):</li> </ul> Thank You!!  | 7) How many years o   | of practice do you have as a nurse (all settings)?        | N/A              |
| <ul> <li>0-25% of my time is spent in the pediatric ED</li> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> </ul> 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!  | <ul> <li>0-25% of my time is spent in the pediatric ED</li> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> </ul> 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!  | 8) How many years o   | of practice do you have as a nurse in the ED?             | □ N/A            |
| <ul> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> </ul> 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!   | <ul> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> </ul> 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!   | 9) Please indicate th | e amount of time spent in the pediatric emergency depa    | rtment (PED):    |
| <ul> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> </ul> 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!   | <ul> <li>26-50% of my time is spent in the pediatric ED</li> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> </ul> 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!   | 0-25% of r            | ny time is spent in the pediatric ED                      |                  |
| <ul> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> <li>10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc):</li> </ul> Thank You!!  | <ul> <li>51-75% of my time is spent in the pediatric ED</li> <li>76-100% of my time is spent in the pediatric ED</li> <li>10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc):</li> </ul> Thank You!!  |                       |   |                  |
| 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!   | 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!   |                       |   |                  |
| physician, resident, physician or nurse from other service [specify], etc):<br>Thank You!!  | physician, resident, physician or nurse from other service [specify], etc): Thank You!!   |                       |   |                  |
| physician, resident, physician or nurse from other service [specify], etc):<br>Thank You!!  | physician, resident, physician or nurse from other service [specify], etc): Thank You!!   |                       |   |                  |
| Thank You!!   | Thank You!!   |                       |   | se, attending ED |
|   |   | physician, residen    | t, physician or nurse from other service [specify], etc): |                  |
|   |   | _                     |   |                  |
|   |   |                       | $\sim$  |                  |
|   |   |                       |   |                  |
|   |   |                       | Thank You!!   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |
|   |   |                       |   |                  |



| REB #: Pro00095418          | Screening     | ID Enrolment Date            |
|-----------------------------|---------------|------------------------------|
| PI: Dr. Samina Ali          | VR            | / / <u>2 0</u><br>/ dd mmm y |
| Discharge Informatio        | n             |                              |
| Disposition                 |               | Discharged Home              |
|                             |               | Admitted                     |
|                             |               | Other,                       |
|                             |               | /                            |
| Date & Time of Discharge f  | rom the ED    | dd mmm yyyy                  |
| 5                           |               | :                            |
|                             |               | (24 hour clock)              |
| Length of Stay in ED (calcu | lated field): | hours                        |
| Discharge Diagnosis         |               |                              |
|                             |               |                              |
|                             |               |                              |
|                             |               |                              |



| REB #: Pro00095418  | Screening ID  | Enrolment Date           |
|---|---|--------------------------|
| PI: Dr. Samina Ali  | VR  | // <u>2 0</u> / dd mmyyy |
| RA Satisfaction G   | Questionnaire (For Standard Care group,                                   | answer Q6 ONLY)          |
| ) Could you please rat  | te the following on a scale of 1-5, where 1= Not a                        | t all and 5=Very much    |
|   |   | 1 2 3 4 5                |
|   | ction with the Virtual Reality (VR) device today                          |                          |
| Ease of set-up of th  |   |                          |
| Your satisfaction wi<br>device                                    | ith the amount of time it took to set up the VR                           |                          |
| Your desire to work   | with the VR device again  |                          |
|   | nuch time was needed to set up the VR device w<br>and questionnaire time) | ith the child, today?    |
| minutes   |   |                          |
| <ul><li>VR Goggles</li><li>Controller</li><li>Headphone</li></ul> |   |                          |
|   | s / neadset kept on for the entire duration of the                        | procedure:               |
| □ No  |   |                          |
| i) What applications / g  | game(s) did the child play during the procedure?                          |                          |
| Check all that apply. If  | et / Smartphone 🗌 Other; s  |                          |
| ) Did you have any teo  | chnical or other issues with operating / handing th<br>y:                 | • •                      |
| Yes; specify  |   |                          |



#### A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children:

| The | VR | Stu | dy |
|-----|----|-----|----|
|-----|----|-----|----|

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# **Adverse Events Log**

|     | To be filled out by Research Assistant |   |  |   |   |  | be filled out            | by Site Investig  | ator        |                       |
|-----|--|---|--|---|---|--|--------------------------|---|-------------|-----------------------|
| No. | Description of Adverse Event           | Onset<br>Date &<br>Time<br>(dd/mmm/<br>yyyy<br>HH:MM) | Action Taken<br>1.None<br>2.Medication<br>3.New or<br>Prolonged<br>Hospitalization<br>4.Procedure /<br>Surgery<br>5.Other, specify | Outcome<br>1. Resolved<br>2. Resolved with<br>Sequelae<br>3. Resolving<br>4. Unresolved<br>5. Fatal<br>6. Lost to follow-up | Date & Time<br>Resolved<br>(dd/mmm/<br>yyyy<br>HH:MM) | Intensity<br>grade:<br>1. Mild<br>2. Moderate<br>3. Severe | Expected<br>AE?<br>Y / N | Relationship<br>to Study<br>1.Unrelated<br>2.Unlikely<br>3.Possible<br>4.Probable<br>5.Definite | SAE?<br>Y/N | Site<br>PI<br>Initial |
| 1   |  |   |  | 191   | ien   |  |                          |   |             |                       |
| 2   |  |   |  |   |   | 0nj  |                          |   |             |                       |
| 3   |  |   |  |   |   |  |                          |   |             |                       |



#### A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

| REB #: Pro00095418 | Screening ID | Enrolment Date                |
|--------------------|--------------|-------------------------------|
| PI: Dr. Samina Ali | VR           | / / <u>2 0</u><br>dd mmm yyyy |

# Early Withdrawal

#### ONLY fill out this form in the event of an early withdrawal

| dd mmm yyyy  |
|--|
| Adverse Event / Serious Adverse Event Death Withdrawal of Consent / Assent Protocol Violation, Specify |
| Other, Specify   |
| ☐ Yes ☐ No<br>☐ Yes ☐ No   |
|  |
| 2  |
|  |
|  |

# Reporting checklist for protocol of a clinical trial.

|  |            | Reporting Item  | Page Number   |
|--|------------|---|---------------|
| Title  | <u>#1</u>  | Descriptive title identifying the study design,<br>population, interventions, and, if applicable, trial<br>acronym  | 1             |
| Trial registration   | <u>#2a</u> | Trial identifier and registry name. If not yet registered, name of intended registry  | 1             |
| Trial registration:<br>data set                                  | <u>#2b</u> | All items from the World Health Organization<br>Trial Registration Data Set   | 5-7 (Table 1) |
| Protocol version   | <u>#3</u>  | Date and version identifier   | 2             |
| Funding  | <u>#4</u>  | Sources and types of financial, material, and other support   | 14            |
| Roles and<br>responsibilities:<br>contributorship                | <u>#5a</u> | Names, affiliations, and roles of protocol contributors   | 15            |
| Roles and<br>responsibilities:<br>sponsor contact<br>information | <u>#5b</u> | Name and contact information for the trial sponsor  | 5             |
| Roles and<br>responsibilities:<br>sponsor and funder             | <u>#5c</u> | Role of study sponsor and funders, if any, in<br>study design; collection, management, analysis,<br>and interpretation of data; writing of the report;<br>and the decision to submit the report for<br>publication, including whether they will have<br>ultimate authority over any of these activities | 14            |
| Roles and<br>responsibilities:<br>committees                     | <u>#5d</u> | Composition, roles, and responsibilities of the<br>coordinating centre, steering committee,<br>endpoint adjudication committee, data<br>management team, and other individuals or   | N/A           |
|  | For peer   | review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml  |               |

|  |             | BMJ Open   | Page 50 of 55 |
|--|-------------|--|---------------|
|  |             | groups overseeing the trial, if applicable (see<br>Item 21a for data monitoring committee)   |               |
| Background and rationale                             | <u>#6a</u>  | Description of research question and justification<br>for undertaking the trial, including summary of<br>relevant studies (published and unpublished)<br>examining benefits and harms for each<br>intervention         | 4-5           |
| Background and<br>ationale: choice of<br>comparators | <u>#6b</u>  | Explanation for choice of comparators  | 7-8           |
| Objectives   | #7          | Specific objectives or hypotheses  | 5             |
| Trial design   | <u>#8</u>   | Description of trial design including type of trial<br>(eg, parallel group, crossover, factorial, single<br>group), allocation ratio, and framework (eg,<br>superiority, equivalence, non-inferiority,<br>exploratory) | 5             |
| Study setting  | <u>#9</u>   | Description of study settings (eg, community<br>clinic, academic hospital) and list of countries<br>where data will be collected. Reference to where<br>list of study sites can be obtained                            | 7             |
| Eligibility criteria                                 | <u>#10</u>  | Inclusion and exclusion criteria for participants.<br>If applicable, eligibility criteria for study centres<br>and individuals who will perform the<br>interventions (eg, surgeons, psychotherapists)                  | 7             |
| Interventions:<br>description                        | <u>#11a</u> | Interventions for each group with sufficient<br>detail to allow replication, including how and<br>when they will be administered   | 7-8           |
| Interventions:<br>modifications                      | <u>#11b</u> | Criteria for discontinuing or modifying allocated<br>interventions for a given trial participant (eg,<br>drug dose change in response to harms,<br>participant request, or improving / worsening<br>disease)           | 9,13          |
|  | For peer    | review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |               |

| 1<br>2<br>3<br>4<br>5<br>6<br>7  | Interventions:<br>adherance        | <u>#11c</u> | Strategies to improve adherence to intervention<br>protocols, and any procedures for monitoring<br>adherence (eg, drug tablet return; laboratory<br>tests)  | 9                |
|--|------------------------------------|-------------|---|------------------|
| 8<br>9<br>10<br>11   | Interventions:<br>concomitant care | <u>#11d</u> | Relevant concomitant care and interventions that<br>are permitted or prohibited during the trial  | 8                |
| 12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20<br>21<br>22<br>23<br>24       | Outcomes                           | <u>#12</u>  | Primary, secondary, and other outcomes,<br>including the specific measurement variable (eg,<br>systolic blood pressure), analysis metric (eg,<br>change from baseline, final value, time to event),<br>method of aggregation (eg, median, proportion),<br>and time point for each outcome. Explanation of<br>the clinical relevance of chosen efficacy and<br>harm outcomes is strongly recommended | 10-11            |
| 24<br>25<br>26<br>27<br>28<br>29<br>30<br>31<br>32                               | Participant timeline               | <u>#13</u>  | Time schedule of enrolment, interventions<br>(including any run-ins and washouts),<br>assessments, and visits for participants. A<br>schematic diagram is highly recommended (see<br>Figure)  | 8-9 and Figure 3 |
| 33<br>34<br>35<br>36<br>37<br>38<br>39<br>40                                     | Sample size                        | <u>#14</u>  | Estimated number of participants needed to<br>achieve study objectives and how it was<br>determined, including clinical and statistical<br>assumptions supporting any sample size<br>calculations   | 11               |
| 41<br>42<br>43<br>44   | Recruitment                        | <u>#15</u>  | Strategies for achieving adequate participant<br>enrolment to reach target sample size  | 11               |
| 45<br>46<br>47<br>48<br>49<br>50<br>51<br>52<br>53<br>54<br>55<br>56<br>57<br>58 | Allocation: sequence<br>generation | <u>#16a</u> | Method of generating the allocation sequence<br>(eg, computer-generated random numbers), and<br>list of any factors for stratification. To reduce<br>predictability of a random sequence, details of<br>any planned restriction (eg, blocking) should be<br>provided in a separate document that is<br>unavailable to those who enrol participants or<br>assign interventions                       | 8                |
| 59<br>60   |                                    | For peer    | review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml  |                  |

#### Page 52 of 55

#### BMJ Open

| 1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>3<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>11<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>4<br>5<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>3<br>4<br>5<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>3<br>4<br>5<br>5<br>6<br>7<br>8<br>9<br>0<br>1<br>2<br>5<br>3<br>4<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5 | Allocation<br>concealment<br>mechanism         | <u>#16b</u> | Mechanism of implementing the allocation<br>sequence (eg, central telephone; sequentially<br>numbered, opaque, sealed envelopes), describing<br>any steps to conceal the sequence until<br>interventions are assigned  | 8   |
|--|--|-------------|--|---|
|  | Allocation:<br>implementation                  | <u>#16c</u> | Who will generate the allocation sequence, who<br>will enrol participants, and who will assign<br>participants to interventions  | 8   |
|  | Blinding (masking)                             | <u>#17a</u> | Who will be blinded after assignment to<br>interventions (eg, trial participants, care<br>providers, outcome assessors, data analysts), and<br>how   | 8   |
|  | Blinding (masking):<br>emergency<br>unblinding | <u>#17b</u> | If blinded, circumstances under which<br>unblinding is permissible, and procedure for<br>revealing a participant's allocated intervention<br>during the trial  | N/A   |
|  | Data collection plan                           | <u>#18a</u> | Plans for assessment and collection of outcome,<br>baseline, and other trial data, including any<br>related processes to promote data quality (eg,<br>duplicate measurements, training of assessors)<br>and a description of study instruments (eg,<br>questionnaires, laboratory tests) along with their<br>reliability and validity, if known. Reference to<br>where data collection forms can be found, if not<br>in the protocol | 8-9<br>and Appendix 2 for Case<br>Report Form |
|  | Data collection plan:<br>retention             | <u>#18b</u> | Plans to promote participant retention and<br>complete follow-up, including list of any<br>outcome data to be collected for participants<br>who discontinue or deviate from intervention<br>protocols  | 9   |
| 60   |  | For peer    | review only - http://bmjopen.bmj.com/site/about/guidelines.x   | html  |

#### Page 53 of 55

#### BMJ Open

| 1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11                      | Data management  | <u>#19</u>  | Plans for data entry, coding, security, and<br>storage, including any related processes to<br>promote data quality (eg, double data entry;<br>range checks for data values). Reference to<br>where details of data management procedures<br>can be found, if not in the protocol   | 12  |
|--|--|-------------|--|-----|
| 12<br>13<br>14<br>15<br>16<br>17<br>18                                     | Statistics: outcomes                                   | <u>#20a</u> | Statistical methods for analysing primary and<br>secondary outcomes. Reference to where other<br>details of the statistical analysis plan can be<br>found, if not in the protocol  | 11  |
| 19<br>20<br>21<br>22   | Statistics: additional analyses                        | <u>#20b</u> | Methods for any additional analyses (eg, subgroup and adjusted analyses)   | 11  |
| 23<br>24<br>25<br>26<br>27<br>28<br>29                                     | Statistics: analysis<br>population and<br>missing data | <u>#20c</u> | Definition of analysis population relating to<br>protocol non-adherence (eg, as randomised<br>analysis), and any statistical methods to handle<br>missing data (eg, multiple imputation)   | 11  |
| 30<br>31<br>32<br>33<br>34<br>35<br>36<br>37<br>38<br>39<br>40<br>41<br>42 | Data monitoring:<br>formal committee                   | <u>#21a</u> | Composition of data monitoring committee<br>(DMC); summary of its role and reporting<br>structure; statement of whether it is independent<br>from the sponsor and competing interests; and<br>reference to where further details about its<br>charter can be found, if not in the protocol.<br>Alternatively, an explanation of why a DMC is<br>not needed | N/A |
| 43<br>44<br>45<br>46<br>47<br>48<br>49                                     | Data monitoring:<br>interim analysis                   | <u>#21b</u> | Description of any interim analyses and stopping<br>guidelines, including who will have access to<br>these interim results and make the final decision<br>to terminate the trial   | N/A |
| 50<br>51<br>52<br>53<br>54<br>55<br>56<br>57<br>58<br>59                   | Harms  | <u>#22</u>  | Plans for collecting, assessing, reporting, and<br>managing solicited and spontaneously reported<br>adverse events and other unintended effects of<br>trial interventions or trial conduct   | 11  |
| 60   |  | For peer    | review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |     |

|            | BMJ Open   |
|------------|--|
| <u>#23</u> | Frequency and procedures for auditing trial<br>conduct, if any, and whether the process will be<br>independent from investigators and the sponsor  |
| <u>#24</u> | Plans for seeking research ethics committee / institutional review board (REC / IRB) approval  |
| <u>#25</u> | Plans for communicating important protocol<br>modifications (eg, changes to eligibility criteria,<br>outcomes, analyses) to relevant parties (eg,<br>investigators, REC / IRBs, trial participants, trial<br>registries, journals, regulators) |
|            |  |

| Consent or assent  | #26a        | Who will obtain informed consent or assent from  | 8   |
|--------------------|-------------|--|-----|
| Consent of assent  | <u>#20a</u> | who will obtain informed consent of assent from  | 0   |
|                    |             | potential trial participants or authorised       |     |
|                    |             | surrogates, and how (see Item 32)                |     |
| Consent or assent: | <u>#26b</u> | Additional consent provisions for collection and | N/A |
| ancillary studies  |             | use of participant data and biological specimens |     |
|                    |             | in ancillary studies, if applicable              |     |
| Confidentiality    | #27         | How personal information about potential and     | 12  |

| 0           |                 |            |  |         |
|-------------|-----------------|------------|--|---------|
| 9           | Confidentiality | <u>#27</u> | How personal information about potential and       | 12      |
| 1           |                 |            | enrolled participants will be collected, shared,   |         |
| 2           |                 |            | and maintained in order to protect confidentiality |         |
| 3<br>4      |                 |            | before, during, and after the trial                |         |
| 5<br>6      | Declaration of  | <u>#28</u> | Financial and other competing interests for        | 13      |
| 7<br>8      | interests       |            | principal investigators for the overall trial and  |         |
| 9           |                 |            | each study site                                    |         |
| 0<br>1<br>2 | Data access     | <u>#29</u> | Statement of who will have access to the final     | Table 1 |
| 3           |                 |            | trial dataset, and disclosure of contractual       |         |

|  |             | investigators   |     |
|--|-------------|---|-----|
| Ancillary and post trial care          | <u>#30</u>  | Provisions, if any, for ancillary and post-trial<br>care, and for compensation to those who suffer<br>harm from trial participation     | N/A |
| Dissemination<br>policy: trial results | <u>#31a</u> | Plans for investigators and sponsor to<br>communicate trial results to participants,<br>healthcare professionals, the public, and other | 13  |

agreements that limit such access for

N/A

14-15

12-13

Auditing

approval

Protocol

amendments

**Research ethics** 

60

#### **BMJ** Open

|   |             | results databases, or other data sharing<br>arrangements), including any publication<br>restrictions  |            |
|---|-------------|---|------------|
| 3Dissemination<br>policy: authorship              | <u>#31b</u> | Authorship eligibility guidelines and any intended use of professional writers  | 15-16      |
| Dissemination<br>policy: reproducible<br>research | <u>#31c</u> | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code   | Table 1    |
| Informed consent<br>materials                     | <u>#32</u>  | Model consent form and other related<br>documentation given to participants and<br>authorised surrogates  | Appendix 1 |
| Biological<br>specimens                           | <u>#33</u>  | Plans for collection, laboratory evaluation, and<br>storage of biological specimens for genetic or<br>molecular analysis in the current trial and for<br>future use in ancillary studies, if applicable | N/A        |
|   |             |   |            |
|   |             |   |            |